1. Biochemistry and Chemical Biology
  2. Epidemiology and Global Health

Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study

  1. Takashi Sasaki  Is a corresponding author
  2. Yoshinori Nishimoto
  3. Takumi Hirata
  4. Yukiko Abe
  5. Nobuyoshi Hirose
  6. Michiyo Takayama
  7. Toru Takebayashi
  8. Hideyuki Okano
  9. Yasumichi Arai
  1. Center for Supercentenarian Medical Research, Keio University School of Medicine, Japan
  2. Department of Neurology, Keio University, School of Medicine, Japan
  3. Institute for Clinical and Translational Science, Nara Medical University, Japan
  4. Houtokukai Utsunomiya Hospital, Japan
  5. Center for Preventive Medicine, Keio University School of Medicine, Japan
  6. Department of Preventive Medicine and Public Health, Keio University School of Medicine, Japan
  7. Department of Physiology, Keio University School of Medicine, Japan
  8. Faculty of Nursing and Medical Care, Keio University, Japan
https://doi.org/10.7554/eLife.86309
Share this article
Cite this article
  1. Takashi Sasaki
  2. Yoshinori Nishimoto
  3. Takumi Hirata
  4. Yukiko Abe
  5. Nobuyoshi Hirose
  6. Michiyo Takayama
  7. Toru Takebayashi
  8. Hideyuki Okano
  9. Yasumichi Arai
(2023)
Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study
eLife 12:e86309.
https://doi.org/10.7554/eLife.86309
  2. Download BibTeX
  3. Download .RIS

Abstract

Background:

High levels of circulating adiponectin are associated with increased insulin sensitivity, low prevalence of diabetes, and low body mass index (BMI); however, high levels of circulating adiponectin are also associated with increased mortality in the 60–70 age group. In this study, we aimed to clarify factors associated with circulating high-molecular-weight (cHMW) adiponectin levels and their association with mortality in the very old (85–89 years of age) and centenarians.

Methods:

The study included 812 (women: 84.4%) for centenarians and 1498 (women: 51.7%) for the very old. The genomic DNA sequence data were obtained by whole-genome sequencing or DNA microarray-imputation methods. Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate regression analyses were used to evaluate cHMW adiponectin characteristics and associated factors. All-cause mortality was analyzed in three quantile groups of cHMW adiponectin levels using Cox regression.

Results:

The cHMW adiponectin levels were increased significantly beyond 100 years of age, were negatively associated with diabetes prevalence, and were associated with SNVs in CDH13 (p=2.21 × 10-22) and ADIPOQ (p=5.72 × 10-7). Multivariate regression analysis revealed that genetic variants, BMI, and high-density lipoprotein cholesterol (HDLC) were the main factors associated with cHMW adiponectin levels in the very old, whereas the BMI showed no association in centenarians. The hazard ratios for all-cause mortality in the intermediate and high cHMW adiponectin groups in very old men were significantly higher rather than those for all-cause mortality in the low-level cHMW adiponectin group, even after adjustment with BMI. In contrast, the hazard ratios for all-cause mortality were significantly higher for high cHMW adiponectin groups in very old women, but were not significant after adjustment with BMI.

Conclusions:

cHMW adiponectin levels increased with age until centenarians, and the contribution of known major factors associated with cHMW adiponectin levels, including BMI and HDLC, varies with age, suggesting that its physiological significance also varies with age in the oldest old.

Funding:

This study was supported by grants from the Ministry of Health, Welfare, and Labour for the Scientific Research Projects for Longevity; a Grant-in-Aid for Scientific Research (No 21590775, 24590898, 15KT0009, 18H03055, 20K20409, 20K07792, 23H03337) from the Japan Society for the Promotion of Science; Keio University Global Research Institute (KGRI), Kanagawa Institute of Industrial Science and Technology (KISTEC), Japan Science and Technology Agency (JST) Research Complex Program "Tonomachi Research Complex" Wellbeing Research Campus: Creating new values through technological and social innovation (JP15667051), the Program for an Integrated Database of Clinical and Genomic Information from the Japan Agency for Medical Research and Development (No. 16kk0205009h001, 17jm0210051h0001, 19dk0207045h0001); the medical-welfare-food-agriculture collaborative consortium project from the Japan Ministry of Agriculture, Forestry, and Fisheries; and the Biobank Japan Program from the Ministry of Education, Culture, Sports, and Technology

Editor's evaluation

This study provides useful descriptive findings regarding levels of adiponectin and its associations with genetic variants and age in very old and centenarian men and women. Due to some missing data, the evidence supporting the conclusions about cross-sectional determinants of circulating levels of adiponectin in centenarians is incomplete. The evidence for conclusions about relationships between adiponectin and survival is also incomplete because of some missing data and unadjusted survival analyses.

https://doi.org/10.7554/eLife.86309.sa0

Introduction

Adiponectin is an adipocyte-derived hormone that plays a vital role in metabolism, including lipid and glucose metabolism, and occurs in circulation at concentrations of up to 0.05% of total plasma protein (Scherer et al., 1995; Ye and Scherer, 2013). Circulating adiponectin forms three major multimer complexes, including a trimer, hexamer, and high-molecular-weight form. Among these forms, circulating high-molecular-weight (cHMW) adiponectin shows more potent biological activity than that of the other two forms (Pajvani et al., 2003). Previous studies in the mouse model studies have shown that cHMW adiponectin enhances insulin sensitivity and plasma lipid clearance; high levels of cHMW adiponectin improve the stability of lipid homeostasis and provided systemic tolerance to obesity under normal physiological conditions (Combs et al., 2004; Qiao et al., 2008; Asterholm and Scherer, 2010). Adiponectin knock-out mice showed mild or moderate insulin resistance, which is exacerbated by a high-fat diet (Kubota et al., 2002; Maeda et al., 2002). However, adiponectin knock-out mice are viable under regular physiological conditions, indicating that adiponectin is not essential for survival under regular dietary conditions (Kubota et al., 2002; Maeda et al., 2002). Therefore, adiponectin function is considered inconspicuous under normal conditions and should become prominent under physiological stress such as hyperglycemia.

In humans, adiponectin shows strong negative associations with body mass index (BMI), the prevalence of type 2 diabetes mellitus (T2DM), and hypertension (Li et al., 2009; Arita et al., 1999; Adamczak et al., 2003). However, high levels of adiponectin have also been associated with an increased risk of cardiovascular disease (CVD) in adults in their 60s and 70s (Kizer et al., 2008; Poehls et al., 2009; Kim-Mitsuyama et al., 2019; Choi et al., 2015). These contradictory findings indicate that environmental and related physiological changes could alter the level and function of adiponectin; therefore, the analysis of adiponectin in adults aged 80 years and older would be essential to elucidate the significance of adiponectin in aging.

Centenarians are individuals aged 100 years and older and characterized by a low incidence of life-threatening diseases, such as CVD and T2DM. They serve as potential models for successful aging (Davey et al., 2012; Arai et al., 2015). Previous studies have reported that cHMW adiponectin levels increase with age and, specifically, that centenarians show comparatively high levels (Arai et al., 2019; Cnop et al., 2003). Low BMI may contribute to high adiponectin levels and insulin resistance in older adults ages above 60 years, and transgenic mouse models have shown prolonged health span and median lifespan. However, the physiological significance of high cHMW adiponectin levels in adults aged above 80 years is still unclear (Muratsu et al., 2021; Li et al., 2021; Cohen et al., 2022). To provide evidence for understanding the physiological function and significance of adiponectin in the oldest old, this study aimed to determine the status and factors associated with cHMW adiponectin levels in 2310 adults aged ≥85 years, including 812 centenarians.

Methods

Study populations

We used data from four prospective cohort studies of the oldest old in Japan: the Tokyo Centenarian Study (TCS) and Japanese Semi-supercentenarian Study (JSS) for centenarians and the Tokyo Oldest Old Survey on Total Health (TOOTH) and Kawasaki Aging Wellbeing Project (KAWP) for the very old (aged 85–99 years). Recruitment was conducted as previously described (Arai et al., 2015; Arai et al., 2014; Gondo et al., 2006; Takayama et al., 2007; Arai et al., 2010; Arai et al., 2021; Sasaki et al., 2021b). From the TCS and JSS, 155 participants were excluded due to a lack of cHMW adiponectin level data; thus, 812 centenarians were enrolled (127 men and 685 women with a median age of 105.3 [interquartile range (IQR): 100.9–106.8] and 106.0 years [IQR: 103.9–107.2], respectively). The TOOTH and KAWP surveys are community-based prospective cohort studies of individuals between 85 and 102 years (TOOTH) and 85 and 90 years (KAWP), respectively. Data for 542 (236 men and 306 women) and 1026 (513 men and 513 women) individual medical examinations are included in the TOOTH and KAWP studies, respectively. Of these, 63 individuals from the TOOTH study were excluded because they were older than 90, and 7 individuals from the KAWP study were excluded due to a lack of cHMW adiponectin level data; thus, 1498 individuals were enrolled as the very old (724 men and 774 women with a median age of 86.9 [IQR: 85.9–88.2] and 87.0 years [IQR: 86.0–88.4], respectively, Figure 1—figure supplements 1, 2, Supplementary file 1).

All of the KAWP, TOOTH, TCS, and JSS have been managed by the Center for Supercentenarian Medical Research, Keio University School of Medicine. Written informed consent was obtained either from the participant or from a proxy if the participant lacked the capacity to provide consent. The ethics committee approved all cohort studies of the Keio University School of Medicine (ID: 20021020, 20022020, 20070047, and 20160297). The TOOTH and KAWP studies are registered in the University Hospital Medical Information Network Clinical Trial Registry (ID: UMIN000001842 and UMIN000026053).

Baseline examination

All participants were examined by experienced geriatricians at the time of enrollment, following previously described protocols (Arai et al., 2015; Arai et al., 2014; Gondo et al., 2006; Takayama et al., 2007; Arai et al., 2010). Our assessment considered medical histories, lifestyle factors, and physical and cognitive functions. A mini-mental state examination (MMSE; 0–30 points) was used to assess cognitive function. The five-item World Health Organization well-being index (WHO5; 0–5 points) was used to assess current mental well-being. Instrumental activities of daily living (IADLs) were assessed using the Lawton scale (0–5 points) and independent IADL was defined as 5 points on the Lawton scale. The concentration of blood biomarkers, including cHMW adiponectin, N-terminal pro-brain natriuretic peptide (NTproBNP), cystatin C, and interleukin-6 (IL-6), was measured according to previously described protocols (Hirata et al., 2020). Blood test results for high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), total cholesterol (TCHO), triglyceride (TG), choline esterase (CHE), aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γGTP), lactate dehydrogenase (LDH), uric acid (UA), albumin (ALB), and HbA1c content were also obtained using previously described protocols (Hirata et al., 2020). A person with diabetes mellitus (DM) was defined as follows: individuals with glycated hemoglobin (HbA1c)≥6.5%, those receiving antidiabetic drug therapy, or those receiving insulin injections (Supplementary file 1).

Measurement of cHMW adiponectin levels

The plasma cHMW adiponectin levels were measured using the Human HMW Adiponectin/Acrp30 Immunoassay Quantikine ELISA Kit (R&D Systems, Inc, Minneapolis, MN, USA) according to the manufacturer’s protocol.

Whole-genome DNA sequencing

Total genomic DNA was extracted from whole blood using a FlexGene DNA Kit (QIAGEN, Hilden, Germany). The whole-genome DNA sequence of 440 centenarians was determined using whole-genome DNA sequencing with previously described protocols (Sasaki et al., 2021a).

Genotyping using DNA microarray and imputation

The genotypes of 0.65 M single nucleotide variants (SNVs) of 367 centenarians were determined using an Axiom Japonica Array NEO according to the manufacturer’s protocol. The genotypes of 0.65 M SNVs of 1015 individuals in the KAWP study were determined using an Infinium Asian Screening Array-24 v1.0 BeadChip kit according to the manufacturer’s protocol. All DNA microarray scan images were analyzed using previously described protocols (Sasaki et al., 2021a).

Meta-quantitative trait association analysis for cHMW adiponectin level

To identify cHMW adiponectin level-associated SNVs in the very old and centenarians, we analyzed the association among cHMW adiponectin level and genetic variants using quantitative trait association analysis with the PLINK program (version 1.90) adjusted for sex and age at entry against 440 WGS and DNA microarray-imputed data for 367 centenarians and 1015 very old, respectively (Purcell et al., 2007). These quantitative trait association analyses were meta-analyzed using Metal (released on May, 5, 2020) (Willer et al., 2010). Finally, we obtained meta-quantitative trait association data between 5.75 M SNVs and cHMW adiponectin levels for 1822 individuals. A Manhattan plot was created using the qqman package (version 0.1.8) in program R (Turner, 2018). An enlarged view of a Manhattan plot with recombination rate information was generated using LocusZoom (version 1.3) (Pruim et al., 2010).

Genotyping and minor allele frequency of rs4783244 (CDH13) and rs11711353 (ADIPOQ)

To determine the rs4783244 and rs11711353 genotypes and minor allele frequency in the very old and centenarians, we genotyped these SNVs using the TaqMan SNP Genotyping Assay system according to the manufacturer’s protocols.

Minor allele frequency of rs4783244 and rs11711353 for Japanese controls (ToMMo 38KJPN) was used in the jMorp database (https://jmorp.megabank.tohoku.ac.jp).

LASSO and multivariate analysis

For Least Absolute Shrinkage and Selection Operator (LASSO) and further multivariate analysis, cHMW adiponectin level was used as the outcome, and LASSO was used to evaluate 32 factors by LASSO including age at entry, BMI, systolic blood pressure (SBP), years of education, smoking history, IADL score, hand grip, cognitive impairment (MMSE: ≤23), WHO5 score, self-reported disease histories (heart disease, diabetes, cancers, renal disease, fracture), biomarkers in blood (HDLC, TCHO, LDLC, TG, CHE, AST, ALT, γGTP, LDH, UA, ALB, CstC, NTproBNP, HbA1c, IL-6), and genetic factors (sex, CDH13 rs4783244, ADIPOQ rs11711353) for the very old, and 26 factors including age at entry, BMI, SBP, five educational category, smoking history, activities of daily living (ADLs) score, self-reported disease histories (heart disease, diabetes, cancers, renal disease, fracture), biomarkers in blood (HDLC, TCHO, LDLC, TG, CHE, γGTP, UA, ALB, CstC, NTproBNP, HbA1c, IL-6), and genetic factors (sex, CDH13 rs4783244, ADIPOQ rs11711353) for centenarians (Supplementary file 1). After excluding samples with any missing values in the selected factors, 1314 very old and 352 centenarians were selected.

Survival analysis

For survival analysis, all-cause, cancer-case, CVD-cause, and pneumonia-cause mortalities were used as outcome, and BMI, cHMW adiponectin level, disease history (DM), number of allele for CDH13 rs4783244 and ADIPOQ rs11711353, age at entry, HDLC, and years of education were used as potential confounder and effect modifiers based on the results of multivariate analysis. The very old and centenarians were grouped into three quantile cHMW adiponectin level groups (high, intermediate, and low) against 1425 very old (678 men and 747 women) and 545 centenarians (90 men and 455 women) for whom survival time information was available.

Statistical analyses

Baseline characteristics, medical history, plasma biomarkers, and genotype data are expressed as a median or number with a percentage or IQR. The difference in baseline data was evaluated using Wilcoxon rank-sum, chi-square, and Fisher’s exact tests (Supplementary file 1). Multivariate logistic regression analyses were performed using a generalized linear model with factors selected by LASSO. All statistical analyses were performed using program R (version 4.0.3) with exactRankTests (wilcox.exact, Wilcoxon rank-sum test [version 0.8-31]), glmnet (LASSO and multivariate analyses [version 4.1]), survival (survival analysis (survfit, coxph, and cox.zph) [version 3.2-13]), powerSurvEpi (statistic power calculation [version 0.1.3]), and default packages.

Results

Baseline characteristics of the very old and centenarian cohorts

This study used data collected from prospective cohort studies, including the TOOTH and KAWP for the very old (aged 85–89 years) as well as the TCS and JSS for centenarians (aged 100 years and older, Figure 1a; Arai et al., 2015; Arai et al., 2014; Gondo et al., 2006; Takayama et al., 2007; Arai et al., 2010; Arai et al., 2021; Sasaki et al., 2021b). The data for cHMW adiponectin levels were available for 812 centenarians (woman: 84.4%, 87.7% in Japanese census data in 2020) and 1498 very old (woman: 51.7%, 64.4% in Japanese census data in 2020, Figure 1—figure supplement 1). Participant characteristics at enrollment are presented in Supplementary file 1. The flowchart for the analysis is shown in Figure 1—figure supplement 2.

Figure 1 with 3 supplements see all
Download asset Open asset
Analysis workflow and distribution of circulating high-molecular-weight (cHMW) adiponectin levels in the very old and centenarians.

(a) Sample summary and analysis workflow of cHMW adiponectin levels. (b) Distribution of cHMW adiponectin levels in older adults and centenarians. cHMW adiponectin levels gradually increased with age in the very old to centenarians. (c) Distribution of cHMW adiponectin levels in older men and women. (d) Distribution of cHMW adiponectin levels in centenarian men and women. The difference in cHMW adiponectin levels was significant between sexes in both the very old and centenarians.

Figure 1—source data 1

Source data for Figure 1 including 812 centenarians and 1498 very old data.

https://cdn.elifesciences.org/articles/86309/elife-86309-fig1-data1-v2.csv

cHMW adiponectin levels increased with age from 30 to 70 years and are higher in women than those in men (Cnop et al., 2003). Our findings in this study were consistent in that cHMW adiponectin levels gradually increased with age (Figure 1b; also observed in the longitudinal data of the TOOTH study, Figure 1—figure supplement 3), with a similar difference observed between sexes of the very old and centenarians (Figure 1c and d).

Single nucleotide variations in the promoter regions of CDH13 and ADIPOQ were associated with cHMW adiponectin levels in the very old and centenarians

A previous genome-wide association study (GWAS) has revealed that cHMW adiponectin levels are associated with two major loci, including CDH13 (also called T-cadherin) and ADIPOQ (gene corresponding to adiponectin), both in European and multi-ethnic cohorts (Dastani et al., 2012). To confirm this association in the very old and centenarians, we quantitatively assessed 5.75 M SNVs adjusted for age at entry and sex from the genome data for 1822 individuals, including whole-genome DNA sequences for 440 centenarians, imputed microarray analysis data for 367 centenarians, and imputed microarray analysis data for 1015 very old (Figure 2a, Figure 2—figure supplement 1). We found that rs12051213 T>C SNV, located near exon 1 of CDH13, was the locus most significantly associated with cHMW adiponectin levels (p=2.21 × 10–22, Z score = –9.73), and rs11711353 A>G SNV, located near exon 1 of ADIPOQ, was the second-most significant locus (p=5.72 × 10–7, Z score = 5.00). The GWAS results also revealed that rs12051213, rs11711353, and other associated SNVs were mainly located around exon 1, indicating that these variants would be associated with the expression of CDH13 and ADIPOQ genes (Figure 2b and c). For the CDH13 locus, rs4783244 (p=5.39 × 10–22, Z score = –9.64) was located near rs12051213, another SNV commonly used as cHMW adiponectin level-associated SNV; therefore, we selected rs4783244 as a representative SNV among CDH13-associated SNVs. To confirm the association between these SNVs and cHMW adiponectin levels, we determined the genotype of these two SNVs against the very old and centenarians using a TaqMan assay. As a result, no significant difference in minor allele frequency was found between Japanese control (ToMMo 38KJPN), the very old, and centenarian men and women using Fisher’s exact test and multiple testing (Figure 2—figure supplement 2). We compared the genotype-based distribution of cHMW adiponectin levels by genotype (Figure 2d, Figure 2—figure supplement 2). cHMW adiponectin levels were found to vary significantly between the rs4783244 reference allele homozygote and rs4783244 alternative allele heterozygote both in the very old and centenarians. However, except for very old men, no significant difference was observed between the rs4783244 alternative allele heterozygote and rs4783244 alternative allele homozygote in the very old or centenarians. Additionally, cHMW adiponectin levels varied significantly among several allele combinations of rs11711353 in very old or centenarian women but not in very old or centenarian men (Figure 2—figure supplement 3). These data indicated that both major loci (rs4783244 of CDH13 and rs11711353 of ADIPOQ) were associated with cHMW adiponectin levels in the very old and centenarians. However, the effects depended on age and sex.

Figure 2 with 3 supplements see all
Download asset Open asset
Meta-genome-wide association study (GWAS) for circulating high-molecular-weight (cHMW) adiponectin levels in the very old and centenarians.

(a) Meta-GWAS analysis for cHMW adiponectin levels in the very old and centenarians. Number of samples for the very old and centenarian were 1015 and 807, respectively. Loci for CDH13 (rs12051213, C: reference allele, T: alternative allele, p=2.45 × 10–22) and ADIPOQ (rs11711353, G: reference allele, A: alternative allele, p=6.68 × 10–7) were detected using meta-GWAS for cHMW adiponectin levels in older adults and centenarians. (b) A GWAS enlarged view of the CDH13 region. (c) A GWAS enlarged view of the ADIPOQ region. (d) Distribution of cHMW adiponectin levels in rs4783244 (CDH13) genotypes of the very old and centenarians. cHMW adiponectin levels varied significantly between the rs4783244 reference allele homozygote and rs4783244 alternative allele heterozygote in the very old and centenarians. Except in very old men, no significant difference was observed between the rs4783244 alternative allele heterozygote and rs4783244 alternative allele homozygote in the very old or centenarians.

Figure 2—source data 1

Source data for Figure 1 including 812 centenarians and 1498 very old data.

https://cdn.elifesciences.org/articles/86309/elife-86309-fig2-data1-v2.csv

The characteristics of cHMW adiponectin levels in the very old and centenarians

A previous study reported a negative association between cHMW adiponectin levels and T2DM prevalence and BMI, as well as a positive association with insulin sensitivity index, TG content, and HDLC levels (Li et al., 2009; Cnop et al., 2003). To evaluate these associations in the oldest old, we analyzed the association between cHMW adiponectin levels and DM, HDLC, and BMI (Figure 3). A person with DM was defined as follows: individuals with glycated hemoglobin (HbA1c)≥6.5%, those receiving antidiabetic drug therapy, or those receiving insulin injections (Figure 3a and b). We found that cHMW adiponectin levels in the DM group were significantly lower than those in the non-DM group in both the very old and centenarians, indicating that adiponectin is associated with the DM pathway, regardless of age.

Figure 3
Download asset Open asset
Association between circulating high-molecular-weight (cHMW) adiponectin level, high-denisty lipoprotein cholesterol (HDLC), body mass index (BMI), and glycated hemoglobin (HbA1c).

(a, b) Distribution of cHMW adiponectin levels in the diabetes mellitus (DM) and non-DM groups. A person with DM was defined as follows: individuals with glycated hemoglobin (HbA1c)≥6.5%, those receiving antidiabetic drug therapy, or those receiving insulin injections. cHMW adiponectin levels in the DM group were significantly lower than those in the non-DM group in the very old and centenarians. (c, d) Association between cHMW adiponectin levels and HDLC content. A positive association was observed between cHMW adiponectin levels and HDLC content in the very old and centenarians. (e, f) Association between cHMW adiponectin levels and BMI. A strong negative association was observed between cHMW adiponectin levels and BMI in the very old, though this association was rarely observed in centenarians.

Figure 3—source data 1

Source data for Figure 1 including 812 centenarians and 1498 very old data.

https://cdn.elifesciences.org/articles/86309/elife-86309-fig3-data1-v2.csv

Although blood-lipid contents, including TCHO, HDLC, LDLC, and TG gradually decreased with age from the very old to centenarians (Supplementary file 1), a positive association was observed between cHMW adiponectin and HDLC levels (Figure 3c, d). A negative association between cHMW adiponectin levels and BMI was observed in the very old, though this association was less prominent in centenarians (Figure 3e, f). These findings suggested that the physiological factors associated with adiponectin may vary from the very old to centenarians.

The factors associated with cHMW adiponectin levels vary between the very old and centenarians

In our multivariate regression analysis of cHMW adiponectin levels, we initially selected 32 factors for the very old, including cHMW adiponectin level-associated genetic factors (genotypes of rs4783244 in CDH13 and rs11711353 in ADIPOQ), and 26 factors for centenarians based on a previous report (Cnop et al., 2003; Muratsu et al., 2021). To reduce the effects of multicollinearity, we used a LASSO method with fivefold cross-validation and identified 19 factors for the very old and 7 factors for centenarians (Figure 4—figure supplement 1). According to the multivariate regression analysis for the very old, 14 significant factors for men and 10 significant factors for women were identified (Figure 4a, Supplementary files 2–4); among centenarians, three significant factors for men and four significant factors for women were identified (Figure 4b, Supplementary files 5–7). An analysis of deviance revealed that the total variance of known cHMW adiponectin level-associated factors was 36.8–42.0% in the very old and centenarian men and 18.4% in centenarian women (Figure 4c, d, Supplementary files 8–11). These results suggest that the genotypes of rs4783244 in CDH13, HDLC, BMI, and lipid metabolism-associated factors, including HDLC and TG, are major factors associated with cHMW adiponectin levels in both sexes of the very old. Furthermore, the genotypes of rs4783244 in CDH13 and HDLC were also associated with cHMW adiponectin levels in centenarians. Significantly, the current known factors associated with cHMW adiponectin levels were expected to correspond to 18.4% of the total variance in centenarian women, indicating a reduced contribution of known factors associated with cHMW adiponectin levels in centenarians. Thus, major cHMW adiponectin-associated factors found in the very old would not be responsible for the age-dependent increment of cHMW adiponectin levels.

Figure 4 with 1 supplement see all
Download asset Open asset
Multivariate analysis for circulating high-molecular-weight (cHMW) adiponectin levels in the very old and centenarians.

(a) Multivariate analysis for cHMW adiponectin levels in very old men and women; 14 significant factors for very old men and 10 significant factors for very old women were identified. (b) Multivariate analysis for cHMW adiponectin levels in centenarian men and women; 3 significant factors for centenarian men and 4 significant factors for centenarian women were identified. (c) The contribution rate for each factor in very old men and women was estimated by analysis of variance. (d) The contribution rate for each factor in centenarian men and women was estimated using analysis of variance. The total variance of known cHMW adiponectin level associated factors corresponded to 36.8–42.0% in very old and centenarian men and 18.4% in centenarian women.

Higher cHMW adiponectin levels in very old men was positively associated with high all-cause mortality rates, independent of BMI

High cHMW adiponectin levels are associated with increased all-cause mortality and CVD risk in adults in their 60s and 70s (Kizer et al., 2008; Poehls et al., 2009; Kim-Mitsuyama et al., 2019; Choi et al., 2015). To evaluate the effects of cHMW adiponectin levels on mortality in the very old and centenarians, hazard ratios of all-cause mortality were analyzed using Cox promotional hazards models for three quantiles of cHMW adiponectin levels (i.e., high, intermediate, and low) in 1425 very old (678 men and 747 women) and 545 centenarians (90 men and 455 women) for whom both survival time information and a number of covariates were available. Prior to the analysis, the availability of sufficient samples and events for all-cause mortality were ensured for the survival analysis of the very old and centenarian women and there was no significant difference in the proportional hazards assumption of the cHMW adiponectin level and each of the covariates (Figure 5—figure supplements 1 and 2). However, the statistical power analysis indicated that there were not sufficient events, and samples were ensured for the centenarian men even if they were divided into two groups. Within the follow-up periods, 145 (21.3%) men and 101 (13.5%) women died in the very old, whereas 89 (98.9%) men and 542 (99.4%) women died in the centenarians (Figure 5 and Supplementary file 1). As a result, the hazard ratios of all-cause mortality for intermediate and high levels of cHMW adiponectin groups in very old men were significantly higher (HR: 1.67 and 2.32) rather than those of the all-cause mortality of the low cHMW adiponectin level group (reference), even after adjustment for BMI (HR: 1.60 and 2.12). In contrast, the hazard ratio for all-cause mortality for the high cHMW adiponectin levels group in very old women was significantly higher (HR: 1.89), but was not significant after adjustment for BMI (HR: 1.41, Figure 5). This trend was also observed in the centenarian women.

Figure 5 with 8 supplements see all
Download asset Open asset
Survival analysis using Cox promotional hazards model for three quantile circulating high-molecular-weight (cHMW) adiponectin level groups.

(a, b) Survival analysis of very old men and women using the Cox promotional hazards model for three quantile cHMW adiponectin level groups. Seven covariates (model1) and seven covariates with body mass index (BMI) were used for calculating the multiple regression analysis of Cox promotional hazards model. Hazard ratio for low concentration adiponectin group was calculated as the reference. The statistics power analysis using powerSurvEpi (version 0.1.3) indicated that survival analyses for both very old men and women have sufficient number of samples and events. (c, d) Survival analysis of the centenarian men and women using Cox promotional hazards model for three quantile cHMW adiponectin level groups. Three covariates (model2) and three covariates with BMI were used for calculation of multiple regression analysis of Cox promotional hazards model. Hazard ratio for low concentration adiponectin group was calculated as the reference. The statistics power analysis using powerSurvEpi (version 0.1.3) indicated that survival analysis for centenarian women has sufficient number of samples and events, however, survival analysis for centenarian men was underpowered due to insufficient number of events.

To further elucidate the factors associated with mortality, we also analyzed cause-specific mortality associated with cancer, CVD, and pneumonia in the very old (Figure 5—figure supplements 3–5). The total number of events for each cause-specific mortality was 59 (cancer), 53 (CVD), and 40 (pneumonia), indicating that the analysis lacked sufficient statistical power. Testing populations with a 5% difference in event frequency would require approximately 440 samples for each group.

Discussion

The results of this study showed that cHMW adiponectin levels increased with age up to centenarians, although the associated factors varied with sex. Therefore, we are further elucidating whether the increment of cHMW adiponectin level with age extends into very old and exceptionally old age. Meta-GWAS with cHMW adiponectin levels revealed that the SNVs of two loci containing the promoter regions of CDH13 and ADIPOQ genes were associated with cHMW adiponectin levels. The levels of HDLC were associated with those of cHMW adiponectin both in the very old and centenarians, though the association with BMI was relatively weaker in centenarians. The multivariate regression analysis with factor selection using the LASSO method revealed that genetic variants, BMI, and lipids were major factors associated with cHMW adiponectin level in the very old; here, BMI was not selected as an associated factor in centenarians. The analysis of deviance revealed that the contribution of known factors to cHMW adiponectin levels decreased in centenarian women, suggesting that the major factors in the very old would not be responsible for the age-dependent increase in cHMW adiponectin levels. The high cHMW adiponectin levels in very old men were associated with all-cause mortality independently of BMI; however, no association was observed between the cHMW adiponectin levels and all-cause mortality in very old and centenarian women. Therefore, the contribution of known major factors associated with cHMW adiponectin levels, including BMI and lipid content, varies with age, suggesting that its physiological significance also varies with age in the oldest old.

The salutary effects of adiponectin on glucose homeostasis, insulin sensitivity, and chronic low-grade inflammation, and the inverse association between the incidence of T2DM and cHMW adiponectin levels are known (Kadowaki et al., 2006; Lindsay et al., 2002; Spranger et al., 2003). We have previously reported that a low incidence of T2DM is a characteristic of centenarians; therefore, we deduced that the high cHMW adiponectin levels in centenarians would be partially influenced by a low incidence of T2DM. In the present study, the T2DM group showed significantly lower levels of cHMW adiponectin, regardless of the cohort, suggesting the physiological significance of cHMW adiponectin levels in the context of insulin sensitivity and T2DM incidence is consistent across ages.

We revealed that very old men with high cHMW adiponectin levels show high rates of all-cause mortality, consistent with previous reports for adults in their 60s and 70s (Kizer et al., 2008; Poehls et al., 2009; Kim-Mitsuyama et al., 2019; Choi et al., 2015). Moreover, cHMW adiponectin levels were associated with all-cause mortality independently of BMI. Excess weight loss can cause frailty in the oldest old, exacerbating mortality rates and death due to pneumonia (Falcone et al., 2012). Based on these results, we deduced that a combination of high cHMW adiponectin levels and low BMI may exert synergistic effects in the mortality among very old men. We also revealed that high cHMW adiponectin levels were not associated with mortality both in very old and centenarian women. Surprisingly, strength of the association between BMI and cHMW adiponectin level decreased in centenarians. Although the major factors associated with cHMW adiponectin level in centenarians were unknown, these results suggest that the factors associated with cHMW adiponectin levels vary with age, which would also alter the physiological significance of cHMW adiponectin level as it relates to mortality.

Frailty is an important concept in health maintenance and the process of functional decline in the oldest old. Recently, plasma adiponectin levels have been positively associated with frailty in the oldest old (Nagasawa et al., 2018; Lee et al., 2021). In our cohort, most centenarians were classified as frail according to the current frailty criteria, so it is difficult to assess frailty in centenarians. For the very old, only the KAWP, one of the cohorts that included the very old, collected sufficient data to assess frailty. Using these limited data for the very old, we analyzed the distribution of cHMW adiponectin levels in each frailty category and analyzed their association with the revised J-CHS frailty index criteria using multiple regression analysis (Satake and Arai, 2020). As a result, we found that cHMW adiponectin levels were significantly associated with frailty, both in very old men and women (Figure 5—figure supplement 6). The cHMW adiponectin level was also significantly associated with frailty in very old women even after adjustment for BMI; however, no significant association was observed in very old men after adjustment by BMI. Thus, cHMW adiponectin levels would be associated with frailty in the very old, especially in women.

Although cHMW adiponectin levels increased with age, their association with BMI was comparatively lower in centenarians than that in the very old. This raises the question of which cells are responsible for the increased expression of adiponectin with aging. One hypothesis is that the clearance mechanism of adiponectin from the blood may be impaired by reduced kidney function, resulting in an accumulation of cHMW adiponectin. However, we did not observe a significant association between the levels of cHMW adiponectin and plasma cystatin C, one of the kidney function markers. Another hypothesis is that aging would cause ectopic ADIPOQ gene expression, increasing cHMW adiponectin levels. Re-analysis of in silico mouse single-cell transcriptomic data revealed that a small number of cells derived from subcutaneous adipose tissue expressed high levels of ADIPOQ, including brown, gonadal, mesenteric, and subcutaneous adipose tissues (Figure 5—figure supplement 7; Tabula Muris Consortium, 2020). Furthermore, a re-analysis of mouse whole-body single-cell transcriptomic data from 24 tissues during 1–30 months of age revealed that ADIPOQ mRNA was rarely expressed in tissues other than the fat tissue, even at advanced ages of 24, 27, and 30 months (Figure 5—figure supplement 8 Tabula Muris Consortium, 2020). These findings indicate that no universal mechanism between humans and mice would exist to induce cHMW adiponectin through ectopic expression of the ADIPOQ gene by aging.

The study had the following limitations: (1) Surveys for centenarians tend to have many missing values due to their limited physical and cognitive function; therefore, multivariate analysis using a series of covariates tends to reduce the number of samples to be analyzed. (2) Although the short survival time of centenarian in this showed no association between cHMW adiponectin level and all-cause mortality in this study, strong factors associated with survival, such as NTproBNP and ALB, tend to be detectable, while weaker factors are more difficult to detect. (3) Cox regression for all-cause mortality in centenarian men and cause-specific mortality in the very old men was statistically underpowered due to the insufficient size of samples and/or events. CVD mortality in very old men showed a trend to be associated with cHMW adiponectin levels, but statistically, twice the number of events or twice the number of total samples are needed to assess this. (4) Analysis of cHMW adiponectin levels and frailty in centenarians is difficult because most centenarians would be classified as frail according to the current frailty criteria. Of the two cohort studies of very old participants, the TOOTH study did not have sufficient data adjusted for the evaluation of J-CHS frailty criteria. Therefore, the association between cHMW adiponectin levels and frailty was analyzed in selected samples derived only from the KAWP study. This was only a cross-sectional analysis, and further analysis would be needed to prove causality. Therefore, these are described only in the Discussion section.

In this study, we verified the association among cHMW adiponectin level, BMI, and all-cause mortality in the very old and centenarians. Due to changes in the physiological significance of BMI between young and old ages, the appropriate BMI value is expected to vary with age. While a low BMI is recommended at a young age due to the risk of diabetes and metabolic syndrome, a high (though not excessively high) BMI is recommended at a later stage of life to decrease the risk of frailty and mortality. Therefore, the biological significance of cHMW adiponectin levels would also be changed depending on the biological significance of BMI in the aging process. The reasons for the high cHMW adiponectin levels and loss of association with BMI in centenarians remain unknown; however, future research should focus on identifying cells that expressing adiponectin, which should clarify its physiological significance in the oldest old.

Data availability

The cHMW adiponectin levels and covariates data were deposited with this manuscript as source data files. The data with age for the very old and centenarians have ethical and legal restrictions to public deposition due to avoid personal identification, and will be available upon request with an appropriate research arrangement with approval of the Research Ethics Committee of Keio University School of Medicine for Clinical Research. To request, please contact Takashi Sasaki (corresponding author) via e-mail: sasasa@z5.keio.jp.

References

    1. Dastani Z
    2. Hivert MF
    3. Timpson N
    4. Perry JRB
    5. Yuan X
    6. Scott RA
    7. Henneman P
    8. Heid IM
    9. Kizer JR
    10. Lyytikäinen LP
    11. Fuchsberger C
    12. Tanaka T
    13. Morris AP
    14. Small K
    15. Isaacs A
    16. Beekman M
    17. Coassin S
    18. Lohman K
    19. Qi L
    20. Kanoni S
    21. Pankow JS
    22. Uh HW
    23. Wu Y
    24. Bidulescu A
    25. Rasmussen-Torvik LJ
    26. Greenwood CMT
    27. Ladouceur M
    28. Grimsby J
    29. Manning AK
    30. Liu CT
    31. Kooner J
    32. Mooser VE
    33. Vollenweider P
    34. Kapur KA
    35. Chambers J
    36. Wareham NJ
    37. Langenberg C
    38. Frants R
    39. Willems-Vandijk K
    40. Oostra BA
    41. Willems SM
    42. Lamina C
    43. Winkler TW
    44. Psaty BM
    45. Tracy RP
    46. Brody J
    47. Chen I
    48. Viikari J
    49. Kähönen M
    50. Pramstaller PP
    51. Evans DM
    52. St Pourcain B
    53. Sattar N
    54. Wood AR
    55. Bandinelli S
    56. Carlson OD
    57. Egan JM
    58. Böhringer S
    59. van Heemst D
    60. Kedenko L
    61. Kristiansson K
    62. Nuotio ML
    63. Loo BM
    64. Harris T
    65. Garcia M
    66. Kanaya A
    67. Haun M
    68. Klopp N
    69. Wichmann HE
    70. Deloukas P
    71. Katsareli E
    72. Couper DJ
    73. Duncan BB
    74. Kloppenburg M
    75. Adair LS
    76. Borja JB
    77. DIAGRAM+ Consortium
    78. MAGIC Consortium
    79. GLGC Investigators
    80. MuTHER Consortium
    81. Wilson JG
    82. Musani S
    83. Guo X
    84. Johnson T
    85. Semple R
    86. Teslovich TM
    87. Allison MA
    88. Redline S
    89. Buxbaum SG
    90. Mohlke KL
    91. Meulenbelt I
    92. Ballantyne CM
    93. Dedoussis GV
    94. Hu FB
    95. Liu Y
    96. Paulweber B
    97. Spector TD
    98. Slagboom PE
    99. Ferrucci L
    100. Jula A
    101. Perola M
    102. Raitakari O
    103. Florez JC
    104. Salomaa V
    105. Eriksson JG
    106. Frayling TM
    107. Hicks AA
    108. Lehtimäki T
    109. Smith GD
    110. Siscovick DS
    111. Kronenberg F
    112. van Duijn C
    113. Loos RJF
    114. Waterworth DM
    115. Meigs JB
    116. Dupuis J
    117. Richards JB
    118. Voight BF
    119. Scott LJ
    120. Steinthorsdottir V
    121. Dina C
    122. Welch RP
    123. Zeggini E
    124. Huth C
    125. Aulchenko YS
    126. Thorleifsson G
    127. McCulloch LJ
    128. Ferreira T
    129. Grallert H
    130. Amin N
    131. Wu G
    132. Willer CJ
    133. Raychaudhuri S
    134. McCarroll SA
    135. Hofmann OM
    136. Segrè AV
    137. van Hoek M
    138. Navarro P
    139. Ardlie K
    140. Balkau B
    141. Benediktsson R
    142. Bennett AJ
    143. Blagieva R
    144. Boerwinkle E
    145. Bonnycastle LL
    146. Boström KB
    147. Bravenboer B
    148. Bumpstead S
    149. Burtt NP
    150. Charpentier G
    151. Chines PS
    152. Cornelis M
    153. Crawford G
    154. Doney ASF
    155. Elliott KS
    156. Elliott AL
    157. Erdos MR
    158. Fox CS
    159. Franklin CS
    160. Ganser M
    161. Gieger C
    162. Grarup N
    163. Green T
    164. Griffin S
    165. Groves CJ
    166. Guiducci C
    167. Hadjadj S
    168. Hassanali N
    169. Herder C
    170. Isomaa B
    171. Jackson AU
    172. Johnson PRV
    173. Jørgensen T
    174. Kao WHL
    175. Kong A
    176. Kraft P
    177. Kuusisto J
    178. Lauritzen T
    179. Li M
    180. Lieverse A
    181. Lindgren CM
    182. Lyssenko V
    183. Marre M
    184. Meitinger T
    185. Midthjell K
    186. Morken MA
    187. Narisu N
    188. Nilsson P
    189. Owen KR
    190. Payne F
    191. Petersen AK
    192. Platou C
    193. Proença C
    194. Prokopenko I
    195. Rathmann W
    196. Rayner NW
    197. Robertson NR
    198. Rocheleau G
    199. Roden M
    200. Sampson MJ
    201. Saxena R
    202. Shields BM
    203. Shrader P
    204. Sigurdsson G
    205. Sparsø T
    206. Strassburger K
    207. Stringham HM
    208. Sun Q
    209. Swift AJ
    210. Thorand B
    211. Tichet J
    212. Tuomi T
    213. van Dam RM
    214. van Haeften TW
    215. van Herpt T
    216. van Vliet-Ostaptchouk JV
    217. Walters GB
    218. Weedon MN
    219. Wijmenga C
    220. Witteman J
    221. Bergman RN
    222. Cauchi S
    223. Collins FS
    224. Gloyn AL
    225. Gyllensten U
    226. Hansen T
    227. Hide WA
    228. Hitman GA
    229. Hofman A
    230. Hunter DJ
    231. Hveem K
    232. Laakso M
    233. Morris AD
    234. Palmer CNA
    235. Rudan I
    236. Sijbrands E
    237. Stein LD
    238. Tuomilehto J
    239. Uitterlinden A
    240. Walker M
    241. Watanabe RM
    242. Abecasis GR
    243. Boehm BO
    244. Campbell H
    245. Daly MJ
    246. Hattersley AT
    247. Pedersen O
    248. Barroso I
    249. Groop L
    250. Sladek R
    251. Thorsteinsdottir U
    252. Wilson JF
    253. Illig T
    254. Froguel P
    255. van Duijn CM
    256. Stefansson K
    257. Altshuler D
    258. Boehnke M
    259. McCarthy MI
    260. Soranzo N
    261. Wheeler E
    262. Glazer NL
    263. Bouatia-Naji N
    264. Mägi R
    265. Randall J
    266. Elliott P
    267. Rybin D
    268. Dehghan A
    269. Hottenga JJ
    270. Song K
    271. Goel A
    272. Lajunen T
    273. Doney A
    274. Cavalcanti-Proença C
    275. Kumari M
    276. Timpson NJ
    277. Zabena C
    278. Ingelsson E
    279. An P
    280. O’Connell J
    281. Luan J
    282. Elliott A
    283. McCarroll SA
    284. Roccasecca RM
    285. Pattou F
    286. Sethupathy P
    287. Ariyurek Y
    288. Barter P
    289. Beilby JP
    290. Ben-Shlomo Y
    291. Bergmann S
    292. Bochud M
    293. Bonnefond A
    294. Borch-Johnsen K
    295. Böttcher Y
    296. Brunner E
    297. Bumpstead SJ
    298. Chen YDI
    299. Chines P
    300. Clarke R
    301. Coin LJM
    302. Cooper MN
    303. Crisponi L
    304. Day INM
    305. de Geus EJC
    306. Delplanque J
    307. Fedson AC
    308. Fischer-Rosinsky A
    309. Forouhi NG
    310. Franzosi MG
    311. Galan P
    312. Goodarzi MO
    313. Graessler J
    314. Grundy S
    315. Gwilliam R
    316. Hallmans G
    317. Hammond N
    318. Han X
    319. Hartikainen AL
    320. Hayward C
    321. Heath SC
    322. Hercberg S
    323. Hillman DR
    324. Hingorani AD
    325. Hui J
    326. Hung J
    327. Kaakinen M
    328. Kaprio J
    329. Kesaniemi YA
    330. Kivimaki M
    331. Knight B
    332. Koskinen S
    333. Kovacs P
    334. Kyvik KO
    335. Lathrop GM
    336. Lawlor DA
    337. Le Bacquer O
    338. Lecoeur C
    339. Li Y
    340. Mahley R
    341. Mangino M
    342. Martínez-Larrad MT
    343. McAteer JB
    344. McPherson R
    345. Meisinger C
    346. Melzer D
    347. Meyre D
    348. Mitchell BD
    349. Mukherjee S
    350. Naitza S
    351. Neville MJ
    352. Orrù M
    353. Pakyz R
    354. Paolisso G
    355. Pattaro C
    356. Pearson D
    357. Peden JF
    358. Pedersen NL
    359. Pfeiffer AFH
    360. Pichler I
    361. Polasek O
    362. Posthuma D
    363. Potter SC
    364. Pouta A
    365. Province MA
    366. Rayner NW
    367. Rice K
    368. Ripatti S
    369. Rivadeneira F
    370. Rolandsson O
    371. Sandbaek A
    372. Sandhu M
    373. Sanna S
    374. Sayer AA
    375. Scheet P
    376. Seedorf U
    377. Sharp SJ
    378. Shields B
    379. Sigurðsson G
    380. Sijbrands EJG
    381. Silveira A
    382. Simpson L
    383. Singleton A
    384. Smith NL
    385. Sovio U
    386. Swift A
    387. Syddall H
    388. Syvänen AC
    389. Tönjes A
    390. Uitterlinden AG
    391. van Dijk KW
    392. Varma D
    393. Visvikis-Siest S
    394. Vitart V
    395. Vogelzangs N
    396. Waeber G
    397. Wagner PJ
    398. Walley A
    399. Ward KL
    400. Watkins H
    401. Wild SH
    402. Willemsen G
    403. Witteman JCM
    404. Yarnell JWG
    405. Zelenika D
    406. Zethelius B
    407. Zhai G
    408. Zhao JH
    409. Zillikens MC
    410. DIAGRAM Consortium
    411. GIANT Consortium
    412. Global B Pgen Consortium
    413. Borecki IB
    414. Meneton P
    415. Magnusson PKE
    416. Nathan DM
    417. Williams GH
    418. Silander K
    419. Bornstein SR
    420. Schwarz P
    421. Spranger J
    422. Karpe F
    423. Shuldiner AR
    424. Cooper C
    425. Serrano-Ríos M
    426. Lind L
    427. Palmer LJ
    428. Hu FB
    429. Franks PW
    430. Ebrahim S
    431. Marmot M
    432. Kao WHL
    433. Pramstaller PP
    434. Wright AF
    435. Stumvoll M
    436. Hamsten A
    437. Procardis Consortium
    438. Buchanan TA
    439. Valle TT
    440. Rotter JI
    441. Penninx B
    442. Boomsma DI
    443. Cao A
    444. Scuteri A
    445. Schlessinger D
    446. Uda M
    447. Ruokonen A
    448. Jarvelin MR
    449. Peltonen L
    450. Mooser V
    451. Sladek R
    452. MAGIC investigators
    453. GLGC Consortium
    454. Musunuru K
    455. Smith AV
    456. Edmondson AC
    457. Stylianou IM
    458. Koseki M
    459. Pirruccello JP
    460. Chasman DI
    461. Johansen CT
    462. Fouchier SW
    463. Peloso GM
    464. Barbalic M
    465. Ricketts SL
    466. Bis JC
    467. Feitosa MF
    468. Orho-Melander M
    469. Melander O
    470. Li X
    471. Li M
    472. Cho YS
    473. Go MJ
    474. Kim YJ
    475. Lee JY
    476. Park T
    477. Kim K
    478. Sim X
    479. Ong RTH
    480. Croteau-Chonka DC
    481. Lange LA
    482. Smith JD
    483. Ziegler A
    484. Zhang W
    485. Zee RYL
    486. Whitfield JB
    487. Thompson JR
    488. Surakka I
    489. Spector TD
    490. Smit JH
    491. Sinisalo J
    492. Scott J
    493. Saharinen J
    494. Sabatti C
    495. Rose LM
    496. Roberts R
    497. Rieder M
    498. Parker AN
    499. Pare G
    500. O’Donnell CJ
    501. Nieminen MS
    502. Nickerson DA
    503. Montgomery GW
    504. McArdle W
    505. Masson D
    506. Martin NG
    507. Marroni F
    508. Lucas G
    509. Luben R
    510. Lokki ML
    511. Lettre G
    512. Launer LJ
    513. Lakatta EG
    514. Laaksonen R
    515. Kyvik KO
    516. König IR
    517. Khaw KT
    518. Kaplan LM
    519. Johansson Å
    520. Janssens A
    521. Igl W
    522. Hovingh GK
    523. Hengstenberg C
    524. Havulinna AS
    525. Hastie ND
    526. Harris TB
    527. Haritunians T
    528. Hall AS
    529. Groop LC
    530. Gonzalez E
    531. Freimer NB
    532. Erdmann J
    533. Ejebe KG
    534. Döring A
    535. Dominiczak AF
    536. Demissie S
    537. Deloukas P
    538. de Faire U
    539. Crawford G
    540. Chen YI
    541. Caulfield MJ
    542. Boekholdt SM
    543. Assimes TL
    544. Quertermous T
    545. Seielstad M
    546. Wong TY
    547. Tai ES
    548. Feranil AB
    549. Kuzawa CW
    550. Taylor HA
    551. Gabriel SB
    552. Holm H
    553. Gudnason V
    554. Krauss RM
    555. Ordovas JM
    556. Munroe PB
    557. Kooner JS
    558. Tall AR
    559. Hegele RA
    560. Kastelein JJP
    561. Schadt EE
    562. Strachan DP
    563. Reilly MP
    564. Samani NJ
    565. Schunkert H
    566. Cupples LA
    567. Sandhu MS
    568. Ridker PM
    569. Rader DJ
    570. Kathiresan S
    (2012) Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals
    PLOS Genetics 8:e1002607.
    https://doi.org/10.1371/journal.pgen.1002607

Decision letter

  1. Edward D Janus
    Reviewing Editor; University of Melbourne, Australia
  2. Carlos Isales
    Senior Editor; Augusta University, United States
  3. Sandra Aleksic
    Reviewer; Albert Einstein College of Medicine, United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Decision letter after peer review:

Thank you for submitting your article "Status and physiological significance of circulating adiponectin in the very old and centenarians: observation study" for consideration by eLife. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Carlos Isales as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Sandra Aleksic (Reviewer #1).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission. We trust that the reviewers' feedback will be helpful to you in preparing the revision.

Essential revisions:

1) Conclusions about survival are not supported by data. Only one adjusted survival analysis is presented (very old men) and in that analysis adiponectin levels were not significantly associated with mortality after adjustment for BMI and other confounders. Other survival analyses are presented as unadjusted KM curves with log-rank tests, frequently with small numbers of participants and with crossing survival curves (questioning the assumption of proportional hazards).

2) One potentially interesting finding is a possible greater mortality in very old men with low BMI and high adiponectin, compared to other combinations of BMI and adiponectin tertiles, including low BMI and mid and low adiponectin, which suggests that it is possible that some of the association between adiponectin and mortality is independent of the BMI at that time point (literature suggests that mortality association of adiponectin is abolished when adjusted for weight loss and low muscle mass in older adults PMID: 29438496).

3) There is a substantial unexplained missingness of data. More than two-thirds of the participants in the very old group are missing mortality data and the reason for this was not provided. More than one-half of centenarians are not included in multivariate analysis of predictors of adiponectin levels and the explanation for the missingness is not provided.

4) There appears to be a missed opportunity to analyze or comment on the prevalence of SNVs associated with adiponectin levels in the centenarians vs. the very old or general background population. Studying centenarians as a phenotype is challenging because one cannot discern whether observed phenotypes are protective ("What got them to centenarian age"), adaptive or maladaptive with regards to aging-related physiologic changes, or an end-of-life phenotype. One exception to this comment is genetic variants that are present in centenarians with different frequencies compared to usual survival populations which can give us an idea about potentially protective (if enriched in centenarians) or detrimental variants (if not present in centenarians) for longevity. It would be interesting to know how the prevalence of identified genetic variants associated with adiponectin in centenarians compares to usual survival populations' prevalence as this could hint if adiponectin is protective or detrimental for exceptional longevity.

5) Some of the key covariates may need redefining. For instance, the paper describes that diabetes mellitus was defined by the level of A1c, without mention of the use of diabetes medications (a person with A1c of <6.5% might still have diabetes which is treated). BMI categorization should be reconsidered as a metabolic risk in Asian populations that occurs at lower levels of BMI, which is why many researchers and clinicians define overweight and obesity at lower BMI levels in Asian individuals.

6) What was the significance of taking the age range 85-89 as very old in this study taking in context with lifespan in the Japanese population? Please clarify. Why was it restricted to a 5-year time period rather than 80-89? Was it something to do with the available cohort?

7) What was the distribution of adiponectin levels in the cohort? Were their outliers present? How were outlier adiponectin levels handled in this study? What was the strategy implemented? Did it have an impact on the study?

8) Please mention the method used in the estimation of Adiponectin in the manuscript as it is the main component. Though from reference it's known that it is estimated by ELISA. Mention that in the manuscript itself as well as standardization and quality checks carried out.

9) Is gender distribution in this study representing population structure? How is the gender distribution of centenarians as well as the very old range in Japan?

10) Have the authors checked the power of the analysis and as well as checked the assumptions of the Cox model? Is the low number of participants in the subset analysis affecting the results? Do highlight in the limitation sections.

11) Authors talk about frailty in the discussion. Has frailty been defined in these cohorts? If so what was the association of adiponectin with frailty in different groups? Grip strength which is discussed is also an important component of physical frailty definition.

Reviewer #1 (Recommendations for the authors):

Previous studies have shown that, while adiponectin is associated with a favorable metabolic profile in the general population (lower BMI, better insulin sensitivity, and healthier lipid profiles), in older people it confers greater risk for mortality, the phenomenon that is sometimes called "adiponectin paradox" (PMID: 29438496). In this study, Sasaki and colleagues aimed to investigate factors associated with circulating high-molecular weight (cHMW) adiponectin levels and the associations between cHMW levels and mortality, among n=1,498 very old (age 85-89 years, 51.7% women) and n=812 centenarians (age >= 100, 84.4% women) from several study cohorts in Japan. This study design is primarily cross-sectional, with longitudinal measurements of adiponectin in a subset of very old participants and follow-up for mortality in another subset of participants. The study confirmed previously published associations between single nucleotide variants (SNV) in genes CDH13 (T-cadherin) and ADIPOQ (adiponectin gene) with adiponectin levels, and that adiponectin levels increase with age. The study also identified that metabolic factors traditionally associated with greater cHMW adiponectin (higher HDL, lower BMI) while associated with adiponectin in very old, have weaker associations with adiponectin in centenarians, especially centenarian men. They also conclude that high levels of cHMW adiponectin in very old men with low BMI are predictive of mortality, while adiponectin was not a significant mortality predictor in very old women or centenarian men or women.

The study provides useful data for the field of metabolic aspects of aging and longevity but it could be strengthened and extended by addressing the noted weaknesses.

Strengths:

– Large cohort of very old and centenarian individuals;

– Longitudinal measurements of adiponectin levels in a subset of participants confirming the observed cross-sectional age trend showing that adiponectin levels continue to increase into a very old age (included data until the age of 90);

– A wide range of available covariates;

– Sex-stratified analyses which address sex as a biological variable;

– Insightful comments about different physiologic meanings of BMI/adiposity in very old and centenarians (higher BMI protective) vs. younger individuals (higher BMI harmful).

Weaknesses:

– Conclusions about survival are not supported by data. Only one adjusted survival analysis is presented (very old men) and in that analysis adiponectin levels were not significantly associated with mortality after adjustment for BMI and other confounders. Other survival analyses are presented as unadjusted KM curves with log-rank tests, frequently with small numbers of participants and with crossing survival curves (questioning the assumption of proportional hazards). One potentially interesting finding is a possible greater mortality in very old men with low BMI and high adiponectin, compared to other combinations of BMI and adiponectin tertiles, including low BMI and mid and low adiponectin, which suggests that it is possible that some of the association between adiponectin and mortality is independent of the BMI at that time point (literature suggests that mortality association of adiponectin is abolished when adjusted for weight loss and low muscle mass in older adults PMID: 29438496).

– There is a substantial unexplained missingness of data. More than two-thirds of the participants in the very old group are missing mortality data and the reason for this was not provided. More than one-half of centenarians are not included in multivariate analysis of predictors of adiponectin levels and the explanation for the missingness is not provided.

– There appears to be a missed opportunity to analyze or comment on the prevalence of SNVs associated with adiponectin levels in the centenarians vs. very old or general background population. Studying centenarians as a phenotype is challenging because one cannot discern whether observed phenotypes are protective ("What got them to centenarian age"), adaptive or maladaptive with regards to aging-related physiologic changes, or an end-of-life phenotype. One exception to this comment is genetic variants that are present in centenarians with different frequencies compared to usual survival populations which can give us an idea about potentially protective (if enriched in centenarians) or detrimental variants (if not present in centenarians) for longevity. It would be interesting to know how the prevalence of identified genetic variants associated with adiponectin in centenarians compares to usual survival populations' prevalence as this could hint if adiponectin is protective or detrimental for exceptional longevity.

– Some of the key covariates may need redefining. For instance, the paper describes that diabetes mellitus was defined by the level of A1c, without mention of the use of diabetes medications (a person with A1c of <6.5% might still have diabetes which is treated). BMI categorization should be reconsidered as a metabolic risk in Asian populations that occurs at lower levels of BMI, which is why many researchers and clinicians define overweight and obesity at lower BMI levels in Asian individuals.

Abstract:

– Consider introducing in the background paragraph that SNVs for adiponectin will be assessed as genetic analysis comes in as a surprise in the next paragraph.

– Suggest including % male/female sex in the method paragraph.

– The statement about survival in the Results section is not supported by data. – Instead of lipid content suggest using lipid levels.

Introduction:

– When asserting that previous studies revealed that cHMW adiponectin enhanced sensitivity to insulin and other metabolic functions (lines 65-68) please specify if these were true causal relationships (presumably obtained with experiments in model organisms); also, the term "flexibility of adipose" is not clear.

– In the sentence that adiponectin knock-out mice were "viable" did the authors mean to say metabolically healthy or non-obese or similar (viable is interpreted as alive) (line 69).

– Consider elaborating more on the statement that "several reports revealed the physiologic significance of adiponectin in aging" (line 85).

– The statement "to elucidate its physiological function and significance in the oldest old" is an overstatement as this could not be done with this type of observational data.

Results:

– Supplementary Table 1 with baseline characteristics, as well as other Supplementary tables referenced in the manuscript were not provided.

– On the other hand, animal data in Supplementary Figures 9 and 10 come as a surprise in the Discussion as this was not mentioned previously; If authors intended to include these analyses, the other parts of the manuscript (abstract, methods, results) should reflect that.

– GWAS results in the text: Please include beats, p values do not tell anything about the effect size or direction.

– Authors mention that the analysis between adiponectin and HbA1c was done, but these results are not provided (line 143).

– The statement that the association between adiponectin and prevalent diabetes indicates that "adiponectin is involved in the T2DM pathway of DM development, regardless of age" (lines 147-8) is a statement of causality that is not supported by cross-sectional observational data.

– The results for total and LDL cholesterol were not provided (149-150).

Discussion

– Please clarify what is the novelty – while associations of adiponectin with age are not novel, this study adds more evidence that this association extends into very old and exceptionally old age.

– Statements of associations between adiponectin and mortality (lines 233-235 and elsewhere in the paper) are not supported by data as they were not independent of the major confounder (BMI), this should be clarified.

– Please consider adding a paragraph on the limitations (and strengths) of this study.

– Authors mention levels of cystatin C but this was not reported.

– As mentioned above, analysis of animal adipose is mentioned in the discussion but not elsewhere (unclear if this was an intended part of the manuscript)

– While the statement that "cHMW adiponectin could be considered a biomarker inversely associated with BMI" is correct, it is not comprehensive, given that high adiponectin is not only a marker of low adiposity but may also be a marker of low muscle mass and weight loss (features of frailty which dramatically increases mortality in older people).

Methods:

– Please elaborate more on the determination of DM status; was anything other than A1c considered (as noted in Public review), and was there any information about the type of DM?

Figures/tables:

– Table 1: consider presenting Cox PH results for other subgroups as well (it would be interesting to know what factors predict survival in centenarians in particular)

– Figure 1: consider removing cartoons depicting study participants as very frail; many very old or even centenarian people are in good health and functional status

– Figure 2 a-c: please clarify if these panels include data from all groups (very old, centenarian, men, women); for those not familiar with GWAS and other genetic analyses consider explaining briefly which alleles are a reference and which alternative.

– Figure 4: color-coding of variables (red, blue, green, orange) is not clear; also, please provide explanations of the abbreviations.

Supplementary tables are missing, including Suppl table 1 which is supposed to include baseline characteristics (with numbers of individuals with missing data hopefully).

– All figures with BMI categories: suggest renaming lowest BMI category to "underweight" as lean may be interpreted as normal BMI; also, BMI over 25 is not considered "obesity".

General:

– Throughout the paper and tables/ graphs: suggest using "very old" instead of "very older".

– Avoid implying causality from cross-sectional associations (another example in line 186).

– Consider including a flowchart that tracks which participants were included in which analyses (n seems to vary quite a bit).

Reviewer #2 (Recommendations for the authors):

High levels of adiponectin are found to be associated with mortality though most of these studies were carried out in age groups less than 80. In this paper, authors take a step forward to understand the distribution of adiponectin distribution in very old (85-89 years old) and centenarians. The authors have successfully presented valuable insights into this distribution as well as looked at its impact on mortality influenced by other physiological factors. Interestingly, authors have also investigated genetic variants associated with adiponectin levels in these groups using genome-wide approaches. This has led to the successful identification of genetic variants in CDH13 and ADIPOQ to be associated with adiponectin expression. In very older men, having low BMI and higher adiponectin levels were found to be a risk for mortality but not for very older women as well as in centenarians.

The positive part of this study is that it provides a picture of adiponectin distribution in these age groups and finds its implications which can be used as a reference study in the field. One concern might be the low sample size in the subgroup analysis where participants were stratified based on adiponectin level and BMI which has to be discussed in the limitation of the study. Another interesting point to look forward to is the impact of age itself in driving outcomes in this study including mortality. In centenarians, more than 99% of participants died in course of the study meaning more than adiponectin, it was complex age-associated multifactorial changes happenings which might be regulating mortality. It would be also interesting to look at the adiponectin levels in the missing age group of 90-100 years in the future.

The manuscript presents a detailed description of cHMW adiponectin levels in the very old and centenarians. Authors have looked at the impact of other factors influencing adiponectin levels including BMI as well as even ran a genome-wide analysis finding significant variants associated with adiponectin expression. Overall this manuscript is well-planned and provides a comprehensive overview of adiponectin and its influences on the elder population. There are some clarifications required.

1) Low incidence of Diabetes was reported in the centenarians. Was it because participants with diabetes were filtered out of the population with age? Will that have an effect on the adiponectin level association with diabetes with age?

2) Participants who were presented with ages between 89-100 were excluded from the analysis. Why are they represented in Figure 1b?

3) High level of Adiponectin was not associated with mortality in centenarians. Is that mainly because age itself is a risk to death or time to death is very low for adiponectin to have an effect? Also, 99% of participants succumbed to death in course of the study.

4) What was the mean or median follow-up time in Cox proportional hazard model in various groups?

5) Was GWAS adjusted for age or just gender? In the methods, its states model was adjusted with gender What other variables were included in the model? If not adjusted with age, why?

6) The writing has been acceptable throughout the manuscript except for the Abstract. I would like the authors to make the abstract more precise.

7) Based on adiponectin level grouping has been done into three groups which had again grouped into multiple groups based on BMI. This might be taking the power of the analysis. Is it possible to have two group classifications like "high" level of adiponectin against "rest" or the reverse and then subgrouping based on BMI?

8) It would be important to highlight a lower number of participants in subgroup analysis. Maybe the lower number of participants influencing the results and maybe it won't be perfect to come up with a precise conclusion. Please highlight these issues in the discussion.

9) Though the recruitment start date might have been referenced in the references mentioned. It would to helpful for readers to have when the study recruitment was started, and the years that followed in the text of the manuscript itself.

"In the very old, 100 (43.1%) men and 95 (32.2%) women died after six years; in centenarians, 122 (99.2%) men and 660 (99.5%) women died until 2016."

Please refer clearly to the start and end points of the analysis.

https://doi.org/10.7554/eLife.86309.sa1

Author response

Essential revisions:

(1) Conclusions about survival are not supported by data. Only one adjusted survival analysis is presented (very old men) and in that analysis adiponectin levels were not significantly associated with mortality after adjustment for BMI and other confounders. Other survival analyses are presented as unadjusted KM curves with log-rank tests, frequently with small numbers of participants and with crossing survival curves (questioning the assumption of proportional hazards).

As noted by the editor and reviewers, several of our previous results included conclusions based on unadjusted survival analyses. The KAWP cohort did not have survival information for the very old. However, we recently had access to the survival information, so we re-analyzed the survival analysis against the very old using the Cox proportional hazards method. We have also added information for the proportional hazards assumption (Supplementary Figures 7-8). In addition, it was not possible to obtain sufficient number of samples and events for centenarian men and cause-specific mortality; this has been stated as a limitation in the Discussion section.

The text was revised as follows;

“Higher cHMW adiponectin levels in very old men was positively associated with high all-cause mortality rates, independent of BMI.

High cHMW adiponectin levels are associated with increased all-cause mortality of CVD risk in adults in their 60s and 70s12, 13, 14, 15. To evaluate the effects of cHMW adiponectin levels on mortality in the very old and centenarians, hazard ratios of all-cause mortality were analyzed using Cox promotional hazards models for three quantiles of cHMW adiponectin levels (i.e., high, intermediate, and low) in 1,425 very old (678 men and 747 women) and 545 centenarians (90 men and 455 women) for whom both survival time information and a number of covariates were available. Prior to the analysis, the availability of sufficient samples and events for all-cause mortality were ensured for the survival analysis of the very old and centenarian women and there was no significant difference in the proportional hazards assumption of the cHMW adiponectin level and each of the covariates (Supplementary Figures 7-8). However, statistical power analysis indicated that there were insufficient events and the samples were ensured for the centenarian men even when they were divided into two groups. Within the follow-up periods, 145 (21.3%) men and 101 (13.5%) women died in the very old, whereas 89 (98.9%) men and 542 (99.4%) women died in the centenarians (Figure 5 and Supplementary File 1). As a result, the hazard ratios of all-cause mortality for intermediate and high levels of cHMW adiponectin groups in very old men were significantly higher (HR: 1.67 and 2.32) rather than those of the all-cause mortality of the low cHMW adiponectin level group (reference), even after adjustment for BMI (HR: 1.60 and 2.12). In contrast, the hazard ratio for all-cause mortality was significantly higher for the high cHMW adiponectin levels group in very old women was significantly higher (HR: 1.89), but was not significant after adjustment for BMI (HR: 1.41, (Figure 5)). This trend was also observed in the centenarian women.

To further elucidate the factors associated with mortality, we also analyzed cause-specific mortality associated with cancer, CVD, and pneumonia in the very old (Figure 5—figure supplements 3–5). The total number of events for each cause-specific mortality was 59 (cancer), 53 (CVD), and 40 (pneumonia), indicating that the analysis lacked sufficient statistical power. Testing populations with a 5% difference in event frequency would require approximately 440 samples for each group.”

“(3) Cox regression for all-cause mortality in centenarian men and cause-specific mortality in the very old men was statistically underpowered due to the insufficient size of samples and/or events. CVD mortality in very old men showed a trend to be associated with cHMW adiponectin levels, but statistically, twice the number of events or twice the number of total samples are needed to assess this.”

(2) One potentially interesting finding is a possible greater mortality in very old men with low BMI and high adiponectin, compared to other combinations of BMI and adiponectin tertiles, including low BMI and mid and low adiponectin, which suggests that it is possible that some of the association between adiponectin and mortality is independent of the BMI at that time point (literature suggests that mortality association of adiponectin is abolished when adjusted for weight loss and low muscle mass in older adults PMID: 29438496).

We thank the reviewers for their careful reading. Previous results of the mortality analysis for the very old were due to the unavailability of mortality data for half of the very old; therefore, we used about half the number of samples. Currently, mortality data are available for the KAWP cohort. We have reanalyzed the results using Cox regression with very old 678 men and 747 women with BMI as a continuous variable. As a result, adiponectin concentration was associated with all-cause mortality independently of BMI (Figure 5).

The text was revised according to question (1).

(3) There is a substantial unexplained missingness of data. More than two-thirds of the participants in the very old group are missing mortality data and the reason for this was not provided. More than one-half of centenarians are not included in multivariate analysis of predictors of adiponectin levels and the explanation for the missingness is not provided.

We apologize if the data conveyed such a remark. At the time of the first submission, the sample size for the mortality analysis was 2/3, due to the unavailability of mortality data for the very old KAWP cohort; these data are now available. Therefore, we have reanalyzed the data for the mortality analysis.

Among the centenarians, there were more missing values due to limitations related to their condition at the time of the survey. Therefore, the analysis was performed on 352 samples with no missing values for 26 variables used in the LASSO multiple regression analysis. As these situations are not comprehensible, a cohort overview and a summary of the number of samples in each analysis have been added as the Supplementary Figures1 and 2. Analyses with many missing values were described as a limitation of the study.

The text was revised as follows;

“This study had the following limitations: (1) Surveys of centenarians tend to have many missing values due to their limited physical and cognitive function; therefore, multivariate analysis using a series of covariates tends to reduce the number of samples to be analyzed.”

(4) There appears to be a missed opportunity to analyze or comment on the prevalence of SNVs associated with adiponectin levels in the centenarians vs. the very old or general background population. Studying centenarians as a phenotype is challenging because one cannot discern whether observed phenotypes are protective ("What got them to centenarian age"), adaptive or maladaptive with regards to aging-related physiologic changes, or an end-of-life phenotype. One exception to this comment is genetic variants that are present in centenarians with different frequencies compared to usual survival populations which can give us an idea about potentially protective (if enriched in centenarians) or detrimental variants (if not present in centenarians) for longevity. It would be interesting to know how the prevalence of identified genetic variants associated with adiponectin in centenarians compares to usual survival populations' prevalence as this could hint if adiponectin is protective or detrimental for exceptional longevity.

We thank you for this constructive suggestion. The allele frequency of cHMW-associated SNVs should have been compared among the Japanese population and our cohorts. Therefore, we have added a comparison of the minor allele frequency (MAF) of SNVs in Japanese controls (database), the very old, and centenarians in Supplementary Figure 5. As a result, there was no systematic MAF difference using Fisher’s exact test and multiple testing, although MAF in ADIPOQ was 3.1% higher in centenarian women. In addition, reviewer2 (5) commented that age should be considered as an adjustment variable in the GWAS, which we completely agree with. Therefore, the GWAS was re-analyzed with age as an adjustment variable.

The text has been revised as follows;

“To confirm the association between these SNVs and cHMW adiponectin levels, we determined the genotype of these two SNVs against the very old and centenarians using a TaqMan assay. As a result, no significant difference in minor allele frequency was found between Japanese control (ToMMo 38KJPN), the very old, and centenarian men and women using Fisher’s exact test and multiple testing (Figure 2—figure supplement 2).”

(5) Some of the key covariates may need redefining. For instance, the paper describes that diabetes mellitus was defined by the level of A1c, without mention of the use of diabetes medications (a person with A1c of <6.5% might still have diabetes which is treated). BMI categorization should be reconsidered as a metabolic risk in Asian populations that occurs at lower levels of BMI, which is why many researchers and clinicians define overweight and obesity at lower BMI levels in Asian individuals.

We thank the reviewer for the valuable suggestion. In line with this, we have redefined the criteria for diabetes mellitus as an individual meeting one or more of the following criteria; (1) HbA1c ≥ 6.5, (2) receiving antidiabetic drug therapy, and (3) receiving insulin injections. Because categorization by the combination of BMI and cHMW adiponectin level is difficult to ensure sufficient statistical power, BMI was entered into the Cox regression as a continuous variable.

The text was revised as follows;

“A person with DM was defined as follows: individuals with glycated hemoglobin (HbA1c) ≥ 6.5%, those receiving antidiabetic drug therapy, or those receiving insulin injections.”

(6) What was the significance of taking the age range 85-89 as very old in this study taking in context with lifespan in the Japanese population? Please clarify. Why was it restricted to a 5-year time period rather than 80-89? Was it something to do with the available cohort?

At baseline, participants in both the TOOTH and KAWP cohorts were over 85 years of age. Therefore, we set the age range for this study at 85–89 years.

(7) What was the distribution of adiponectin levels in the cohort? Were their outliers present? How were outlier adiponectin levels handled in this study? What was the strategy implemented? Did it have an impact on the study?

All data for cHMW adiponectin levels are shown in Figure 1; there are no outliers for cHMW adiponectin levels in this study.

(8) Please mention the method used in the estimation of Adiponectin in the manuscript as it is the main component. Though from reference it's known that it is estimated by ELISA. Mention that in the manuscript itself as well as standardization and quality checks carried out.

We apologize for the lack of information. We have added the method for measuring cHMW adiponectin levels by ELISA in the Methods section.

The text was added as follows;

“Measurement of cHMW adiponectin levels

The plasma cHMW adiponectin levels were measured using the Human HMW Adiponectin/ Acrp30 Immunoassay Quantikine ELISA Kit (R&D Systems, Inc, Minneapolis, MN, USA) according to manufacture protocol.”

(9) Is gender distribution in this study representing population structure? How is the gender distribution of centenarians as well as the very old range in Japan?

According to the 2020 Japanese Census, the proportion of women in the 85–89 age group was 0.644, and the proportion of centenarians was 0.877. This information has been added in the text as follows.

“The data for cHMW adiponectin levels were available for 812 centenarians (woman: 84.4%, 87.7% in Japanese census data in 2020) and 1,498 very old (woman: 51.7%, 64.4% in Japanese census data in 2020, Supplementary Figure 1). Participant characteristics at enrollment are presented in Supplementary Table 1. The flow chart for the analysis is shown in Figure 1—figure supplement 2.”

(10) Have the authors checked the power of the analysis and as well as checked the assumptions of the Cox model? Is the low number of participants in the subset analysis affecting the results? Do highlight in the limitation sections.

We performed a power analysis and confirmed that the all-cause mortality analysis for the very old and centenarian women included sufficient numbers of samples and events. However, centenarian men and cause-specific mortality in the very old population did not have sufficient numbers of samples and events. These are described in the results and mentioned as a limitation in the Discussion section.

“However, the statistical power analysis indicated that there were not sufficient events, and samples were ensured for the centenarian men even if they were divided into two groups.”

“To further elucidate the factors associated with mortality, we also analyzed cause-specific mortality associated with cancer, CVD, and pneumonia in the very old (Figure 5—figure supplements 3–5). The total number of events for each cause-specific mortality was 59 (cancer), 53 (CVD), and 40 (pneumonia), indicating that the analysis lacked sufficient statistical power. Testing populations with a 5% difference in event frequency would require approximately 440 samples for each group.”

“(3) Cox regression for all-cause mortality in centenarian men and cause-specific mortality in the very old men was statistically underpowered due to the insufficient size of samples and/or events. CVD mortality in very old men showed a trend to be associated with cHMW adiponectin levels, but statistically, twice the number of events or twice the number of total samples are needed to assess this.”

(11) Authors talk about frailty in the discussion. Has frailty been defined in these cohorts? If so what was the association of adiponectin with frailty in different groups? Grip strength which is discussed is also an important component of physical frailty definition.

We appreciate this insightful comment. This is a very important point and there are few previous reports on this factor. However, frailty analysis for centenarians is difficult because most centenarians would be classified as frail using the current frailty criteria. For the very old, only the KAWP, one of the very old cohorts, collected sufficient data to calculate frailty.

Therefore, results from previous publications and analyses of selected cohort data in this study have been added to the Discussion section as follows;

“Frailty is an important concept in health maintenance and the process of functional decline in the oldest old. Recently, serum adiponectin levels have been positively associated with frailty in the oldest old34, 35. In our cohort, most centenarians were classified as frail according to the current frailty criteria, so it is difficult to assess frailty in centenarians. For the very old, only the KAWP, one of the cohorts that included the very old, collected sufficient data to assess frailty. Using these limited data for the very old, we analyzed the distribution of cHMW adiponectin levels in each frailty category and analyzed their association with the revised J-CHS frailty index criteria using multiple regression analysis36. As a result, we found that cHMW adiponectin levels were significantly associated with frailty, both in very old men and women (Supplementary File 12). The cHMW adiponectin level was also significantly associated with frailty in very old women even after adjustment for BMI; however, no significant association was observed in very old men after adjustment by BMI. Thus, cHMW adiponectin levels would be associated with frailty in the very old, especially in women.”

“(4) The analysis of cHMW adiponectin levels and frailty in centenarians is difficult because most centenarians would be classified as frail according to the current frailty criteria. Of the two cohort studies of very old participants, the TOOTH study did not have sufficient data adjusted for the evaluation of J-CHS frailty criteria. Therefore, the association between cHMW adiponectin levels and frailty was analyzed in selected samples derived only from the KAWP study only. This was only a cross-sectional analysis, and further analysis would be needed to prove causality. Therefore, these are described only in the Discussion section.”

Reviewer #1 (Recommendations for the authors):

Previous studies have shown that, while adiponectin is associated with a favorable metabolic profile in the general population (lower BMI, better insulin sensitivity, and healthier lipid profiles), in older people it confers greater risk for mortality, the phenomenon that is sometimes called "adiponectin paradox" (PMID: 29438496). In this study, Sasaki and colleagues aimed to investigate factors associated with circulating high-molecular weight (cHMW) adiponectin levels and the associations between cHMW levels and mortality, among n=1,498 very old (age 85-89 years, 51.7% women) and n=812 centenarians (age >= 100, 84.4% women) from several study cohorts in Japan. This study design is primarily cross-sectional, with longitudinal measurements of adiponectin in a subset of very old participants and follow-up for mortality in another subset of participants. The study confirmed previously published associations between single nucleotide variants (SNV) in genes CDH13 (T-cadherin) and ADIPOQ (adiponectin gene) with adiponectin levels, and that adiponectin levels increase with age. The study also identified that metabolic factors traditionally associated with greater cHMW adiponectin (higher HDL, lower BMI) while associated with adiponectin in very old, have weaker associations with adiponectin in centenarians, especially centenarian men. They also conclude that high levels of cHMW adiponectin in very old men with low BMI are predictive of mortality, while adiponectin was not a significant mortality predictor in very old women or centenarian men or women.

The study provides useful data for the field of metabolic aspects of aging and longevity but it could be strengthened and extended by addressing the noted weaknesses.

Strengths:

– Large cohort of very old and centenarian individuals;

– Longitudinal measurements of adiponectin levels in a subset of participants confirming the observed cross-sectional age trend showing that adiponectin levels continue to increase into a very old age (included data until the age of 90);

– A wide range of available covariates;

– Sex-stratified analyses which address sex as a biological variable;

– Insightful comments about different physiologic meanings of BMI/adiposity in very old and centenarians (higher BMI protective) vs. younger individuals (higher BMI harmful).

Weaknesses:

– Conclusions about survival are not supported by data. Only one adjusted survival analysis is presented (very old men) and in that analysis adiponectin levels were not significantly associated with mortality after adjustment for BMI and other confounders. Other survival analyses are presented as unadjusted KM curves with log-rank tests, frequently with small numbers of participants and with crossing survival curves (questioning the assumption of proportional hazards). One potentially interesting finding is a possible greater mortality in very old men with low BMI and high adiponectin, compared to other combinations of BMI and adiponectin tertiles, including low BMI and mid and low adiponectin, which suggests that it is possible that some of the association between adiponectin and mortality is independent of the BMI at that time point (literature suggests that mortality association of adiponectin is abolished when adjusted for weight loss and low muscle mass in older adults PMID: 29438496).

– There is a substantial unexplained missingness of data. More than two-thirds of the participants in the very old group are missing mortality data and the reason for this was not provided. More than one-half of centenarians are not included in multivariate analysis of predictors of adiponectin levels and the explanation for the missingness is not provided.

– There appears to be a missed opportunity to analyze or comment on the prevalence of SNVs associated with adiponectin levels in the centenarians vs. very old or general background population. Studying centenarians as a phenotype is challenging because one cannot discern whether observed phenotypes are protective ("What got them to centenarian age"), adaptive or maladaptive with regards to aging-related physiologic changes, or an end-of-life phenotype. One exception to this comment is genetic variants that are present in centenarians with different frequencies compared to usual survival populations which can give us an idea about potentially protective (if enriched in centenarians) or detrimental variants (if not present in centenarians) for longevity. It would be interesting to know how the prevalence of identified genetic variants associated with adiponectin in centenarians compares to usual survival populations' prevalence as this could hint if adiponectin is protective or detrimental for exceptional longevity.

– Some of the key covariates may need redefining. For instance, the paper describes that diabetes mellitus was defined by the level of A1c, without mention of the use of diabetes medications (a person with A1c of <6.5% might still have diabetes which is treated). BMI categorization should be reconsidered as a metabolic risk in Asian populations that occurs at lower levels of BMI, which is why many researchers and clinicians define overweight and obesity at lower BMI levels in Asian individuals.

Abstract:

– Consider introducing in the background paragraph that SNVs for adiponectin will be assessed as genetic analysis comes in as a surprise in the next paragraph.

– Suggest including % male/female sex in the method paragraph.

Thank you for your suggestions. We have added %male/female sex information in the Method paragraph as follows,

“Methods: The study included 812 (women: 84.4%) for centenarians and 1,498 (women: 51.7%) for the very old.”

– The statement about survival in the Results section is not supported by data. – Instead of lipid content suggest using lipid levels.

Introduction:

– When asserting that previous studies revealed that cHMW adiponectin enhanced sensitivity to insulin and other metabolic functions (lines 65-68) please specify if these were true causal relationships (presumably obtained with experiments in model organisms); also, the term "flexibility of adipose" is not clear.

Thank you for your suggestions. We have changed the sentence as follows:

“Previous studies in the mouse model studies have shown that cHMW adiponectin enhances insulin sensitivity and plasma lipid clearance; high levels of cHMW adiponectin improve the stability of lipid homeostasis and provide systemic tolerance to obesity under normal physiological conditions4, 5, 6.”

– In the sentence that adiponectin knock-out mice were "viable" did the authors mean to say metabolically healthy or non-obese or similar (viable is interpreted as alive) (line 69).

– Consider elaborating more on the statement that "several reports revealed the physiologic significance of adiponectin in aging" (line 85).

– The statement "to elucidate its physiological function and significance in the oldest old" is an overstatement as this could not be done with this type of observational data.

Thank you for your suggestions. We agree with you. We have changed the sentence as follows:

“To provide evidence for understanding the physiological function and significance of adiponectin in the oldest old, this study aimed to determine the status and factors associated with cHMW adiponectin levels in 2,310 adults aged ≥85 years, including 812 centenarians.”

Results:

– Supplementary Table 1 with baseline characteristics, as well as other Supplementary tables referenced in the manuscript were not provided.

– On the other hand, animal data in Supplementary Figures 9 and 10 come as a surprise in the Discussion as this was not mentioned previously; If authors intended to include these analyses, the other parts of the manuscript (abstract, methods, results) should reflect that.

– GWAS results in the text: Please include beats, p values do not tell anything about the effect size or direction.

Accordingly, we have added the Z-score information to the GWAS figure to show the effect size and direction in Figure 2.

– Authors mention that the analysis between adiponectin and HbA1c was done, but these results are not provided (line 143).

We monitored the criteria for DM using HbA1c level, anti-diabetic medication, and insulin injection information because HbA1c level information alone was not sufficient, as indicated by reviewer 1. Therefore, we have deleted this data.

– The statement that the association between adiponectin and prevalent diabetes indicates that "adiponectin is involved in the T2DM pathway of DM development, regardless of age" (lines 147-8) is a statement of causality that is not supported by cross-sectional observational data.

Thank you for pointing this out. We agree with you. We have revised the sentence as follows:

“We found that cHMW adiponectin levels in the DM group were significantly lower than those in the non-DM group in both the very old and centenarians, indicating that adiponectin is associated with the DM pathway, regardless of age.”

– The results for total and LDL cholesterol were not provided (149-150).

This has been included in Supplementary Table 1.

Discussion

– Please clarify what is the novelty – while associations of adiponectin with age are not novel, this study adds more evidence that this association extends into very old and exceptionally old age.

Thank you for the opportunity to provide clarity here. We have revised the sentence as follows:

“The results of this study showed that cHMW adiponectin levels increased with age up to centenarians, although the associated factors varied with sex. Therefore, we are further elucidating whether the increment of cHMW adiponectin level with age extends to very old and exceptionally old age.”

– Statements of associations between adiponectin and mortality (lines 233-235 and elsewhere in the paper) are not supported by data as they were not independent of the major confounder (BMI), this should be clarified.

Thank you for your suggestions. We have added data on the association between death and BMI to Figure 5.

– Please consider adding a paragraph on the limitations (and strengths) of this study.

In light of your comment, we have added a paragraph summarizing the limitations of the study at the end of the Discussion section. The following has been inserted:

“The study had the following limitations: (1) Surveys of centenarian surveys tend to have many missing values due to their limited physical and cognitive function; therefore, multivariate analysis using a series of covariates tends to reduce the number of samples to be analyzed. (2) Although the short survival time of centenarian in this showed no association between cHMW adiponectin level and all-cause mortality in this study, strong factors associated with survival, such as N-terminal pro-brain natriuretic peptide (NTproBNP) and albumin (ALB), tend to be detectable, while weaker factors are more difficult to detect. (3) Cox regression for all-cause mortality in centenarian men and cause-specific mortality in the very old men was underpowered due to the statistically insufficient size of samples and/or events. CVD mortality in very old men showed a trend to be associated with cHMW adiponectin levels, but statistically, twice the number of events or twice the number of total samples are needed to assess this. (4) Analysis of cHMW adiponectin levels and frailty in centenarians is difficult because most centenarians would be classified as frail according to the current frailty criteria. Of the two cohort studies of very old participants, the TOOTH study did not have sufficient data adjusted for J-CHS frailty criteria. Therefore, the association between cHMW adiponectin levels and frailty was analyzed in selected samples from the KAWP study only. This was only a cross-sectional analysis, and further analysis would be needed to prove causality. Therefore, these are described only in the Discussion section.”

– Authors mention levels of cystatin C but this was not reported.

We have supplied cystatin C information in Supplementary Table 1.

– As mentioned above, analysis of animal adipose is mentioned in the discussion but not elsewhere (unclear if this was an intended part of the manuscript)

This analysis was based on the results of another group; therefore, it is not included in the Results section, but only mentioned in the Discussion section.

– While the statement that "cHMW adiponectin could be considered a biomarker inversely associated with BMI" is correct, it is not comprehensive, given that high adiponectin is not only a marker of low adiposity but may also be a marker of low muscle mass and weight loss (features of frailty which dramatically increases mortality in older people).

In view of your comment, we have deleted the discrepant sentence.

Methods:

– Please elaborate more on the determination of DM status; was anything other than A1c considered (as noted in Public review), and was there any information about the type of DM?

Thank you for pointing this out. We have re-defined the criteria for diabetes mellitus and inserted this in the methods section as follows:

“A person with DM was defined as follows: individuals with glycated hemoglobin (HbA1c) ≥ 6.5%, those receiving antidiabetic drug therapy, or those receiving insulin injections (Figure 3a,b).”

Figures/tables:

– Table 1: consider presenting Cox PH results for other subgroups as well (it would be interesting to know what factors predict survival in centenarians in particular)

– Figure 1: consider removing cartoons depicting study participants as very frail; many very old or even centenarian people are in good health and functional status

Thank you for pointing out the inappropriateness of these cartoons. We have removed them accordingly.

– Figure 2 a-c: please clarify if these panels include data from all groups (very old, centenarian, men, women); for those not familiar with GWAS and other genetic analyses consider explaining briefly which alleles are a reference and which alternative.

Thank you for the opportunity to provide clarity here. We have added this information in the legend of Figure 2.

– Figure 4: color-coding of variables (red, blue, green, orange) is not clear; also, please provide explanations of the abbreviations.

We apologize for the lack of clarity here. The information was described in the Supplementary Figure, but not in Figure 4 in the previous version. We have now revised this same and added this information in Figure 4.

Supplementary tables are missing, including Suppl table 1 which is supposed to include baseline characteristics (with numbers of individuals with missing data hopefully).

– All figures with BMI categories: suggest renaming lowest BMI category to "underweight" as lean may be interpreted as normal BMI; also, BMI over 25 is not considered "obesity".

Based on the reviewer's comments, we have considered BMI as a continuous variable in the revised version of the manuscript. As a result, we have removed the BMI category from the manuscript.

General:

– Throughout the paper and tables/ graphs: suggest using "very old" instead of "very older".

We have revised the term throughout the manuscript based on your valuable suggestion.

– Avoid implying causality from cross-sectional associations (another example in line 186).

Thank you for pointing this out. We agree with you. The entire manuscript was reviewed and revised accordingly.

– Consider including a flowchart that tracks which participants were included in which analyses (n seems to vary quite a bit).

Thank you for your suggestion. We have added new Supplementary Figures 1-2, which include a flowchart describing which participants were included in which analyses.

Reviewer #2 (Recommendations for the authors):

High levels of adiponectin are found to be associated with mortality though most of these studies were carried out in age groups less than 80. In this paper, authors take a step forward to understand the distribution of adiponectin distribution in very old (85-89 years old) and centenarians. The authors have successfully presented valuable insights into this distribution as well as looked at its impact on mortality influenced by other physiological factors. Interestingly, authors have also investigated genetic variants associated with adiponectin levels in these groups using genome-wide approaches. This has led to the successful identification of genetic variants in CDH13 and ADIPOQ to be associated with adiponectin expression. In very older men, having low BMI and higher adiponectin levels were found to be a risk for mortality but not for very older women as well as in centenarians.

The positive part of this study is that it provides a picture of adiponectin distribution in these age groups and finds its implications which can be used as a reference study in the field. One concern might be the low sample size in the subgroup analysis where participants were stratified based on adiponectin level and BMI which has to be discussed in the limitation of the study. Another interesting point to look forward to is the impact of age itself in driving outcomes in this study including mortality. In centenarians, more than 99% of participants died in course of the study meaning more than adiponectin, it was complex age-associated multifactorial changes happenings which might be regulating mortality. It would be also interesting to look at the adiponectin levels in the missing age group of 90-100 years in the future.

The manuscript presents a detailed description of cHMW adiponectin levels in the very old and centenarians. Authors have looked at the impact of other factors influencing adiponectin levels including BMI as well as even ran a genome-wide analysis finding significant variants associated with adiponectin expression. Overall this manuscript is well-planned and provides a comprehensive overview of adiponectin and its influences on the elder population. There are some clarifications required.

(1) Low incidence of Diabetes was reported in the centenarians. Was it because participants with diabetes were filtered out of the population with age? Will that have an effect on the adiponectin level association with diabetes with age?

We thank the reviewer for the careful reading. As suggested, this possibility cannot be excluded, so we have added this to the discussion as follows:

“We have previously reported that a low incidence of T2DM is a characteristic of centenarians; therefore, we deduced that the high cHMW adiponectin levels in centenarians would be partially influenced by a low incidence of T2DM.”

(2) Participants who were presented with ages between 89-100 were excluded from the analysis. Why are they represented in Figure 1b?

We apologize for the oversight. We have removed the very old aged 90–99 years from Figure 1B.

(3) High level of Adiponectin was not associated with mortality in centenarians. Is that mainly because age itself is a risk to death or time to death is very low for adiponectin to have an effect? Also, 99% of participants succumbed to death in course of the study.

Thank you for the opportunity to provide clarity here. Even in centenarians, strong factors such as BMI and NTproBNP are associated with all-cause mortality. However, as the reviewer points out, this possibility cannot be excluded; therefore, we have listed these as limitations in the Discussion section as follows.

“(2) Although the short survival time of centenarians in this study showed no association between cHMW adiponectin level and all-cause mortality, strong factors associated with survival, such as N-terminal pro-brain natriuretic peptide (NTproBNP) and albumin (ALB), tend to be detectable, while weaker factors are more difficult to detect.”

(4) What was the mean or median follow-up time in Cox proportional hazard model in various groups?

Accordingly, we have added this information in Supplementary File 1.

(5) Was GWAS adjusted for age or just gender? In the methods, its states model was adjusted with gender What other variables were included in the model? If not adjusted with age, why?

Thank you for your pertinent query. We have re-analyzed all GWAS adjusted with both age and sex.

(6) The writing has been acceptable throughout the manuscript except for the Abstract. I would like the authors to make the abstract more precise.

We apologize if the data conveyed such a remark. We have re-written the abstract as follows, per your suggestion.

“Abstract

Background: High levels of circulating adiponectin are associated with increased insulin sensitivity, low prevalence of diabetes, and low body mass index (BMI); however, high levels of circulating adiponectin are also associated with increased mortality in the 60–70 age group. In this study, we aimed to clarify factors associated with circulating high-molecular-weight (cHMW) adiponectin levels and their association with mortality in the very old (85–89 years old) and centenarians.

Methods: The study included 812 (women: 84.4%) for centenarians and 1,498 (women: 51.7%) for the very old. The genomic DNA sequence data were obtained by whole genome sequencing or DNA microarray-imputation methods. LASSO and multivariate regression analyses were used to evaluate cHMW adiponectin characteristics and associated factors. All-cause mortality was analyzed in three quantile groups of cHMW adiponectin levels using Cox regression.

Results: The cHMW adiponectin levels were increased significantly beyond 100 years of age, were negatively associated with diabetes prevalence, and were associated with SNVs in CDH13 (p = 2.21 × 10-22) and ADIPOQ (p = 5.72 × 10-7). Multivariate regression analysis revealed that genetic variants, BMI, and high-density lipoprotein cholesterol (HDLC) were the main factors associated with cHMW adiponectin levels in the very old, whereas the BMI showed no association in centenarians. The hazard ratios for all-cause mortality in the intermediate and high cHMW adiponectin groups in very old men were significantly higher rather than those for all-cause mortality in the low level cHMW adiponectin group, even after adjustment with BMI. In contrast, the hazard ratios for all-cause mortality were significantly higher for high cHMW adiponectin groups in very old women, but were not significant after adjustment with BMI.

Conclusions: cHMW adiponectin levels increased with age until centenarians, and the contribution of known major factors associated with cHMW adiponectin levels, including BMI and HDLC, varies with age, suggesting that its physiological significance also varies with age in the oldest old.”

(7) Based on adiponectin level grouping has been done into three groups which had again grouped into multiple groups based on BMI. This might be taking the power of the analysis. Is it possible to have two group classifications like "high" level of adiponectin against "rest" or the reverse and then subgrouping based on BMI?

(8) It would be important to highlight a lower number of participants in subgroup analysis. Maybe the lower number of participants influencing the results and maybe it won't be perfect to come up with a precise conclusion. Please highlight these issues in the discussion.

Thank you for pointing this out. We completely agree with you. We have described these points as limitations in the Discussion section as follows,

“(3) Cox regression for all-cause mortality in centenarian men and cause-specific mortality in very old men was underpowered due to the statistically insufficient size of samples and/or events. CVD mortality in very old men showed a trend to be associated with cHMW adiponectin levels, but statistically, twice the number of events or twice the number of total samples are needed to assess this.”

(9) Though the recruitment start date might have been referenced in the references mentioned. It would to helpful for readers to have when the study recruitment was started, and the years that followed in the text of the manuscript itself.

"In the very old, 100 (43.1%) men and 95 (32.2%) women died after six years; in centenarians, 122 (99.2%) men and 660 (99.5%) women died until 2016."

Please refer clearly to the start and end points of the analysis.

Thank you for the opportunity to provide clarity here. We have added described the cohort information in an additional Supplementary Figure1.

https://doi.org/10.7554/eLife.86309.sa2

Article and author information

Author details

  1. Takashi Sasaki

    Center for Supercentenarian Medical Research, Keio University School of Medicine, Tokyo, Japan
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Writing – original draft
    For correspondence
    sasasa@z5.keio.jp
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6275-046X

  2. Yoshinori Nishimoto

    1. Center for Supercentenarian Medical Research, Keio University School of Medicine, Tokyo, Japan
    2. Department of Neurology, Keio University, School of Medicine, Tokyo, Japan
    Contribution
    Data curation, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  3. Takumi Hirata

    1. Center for Supercentenarian Medical Research, Keio University School of Medicine, Tokyo, Japan
    2. Institute for Clinical and Translational Science, Nara Medical University, Nara, Japan
    Contribution
    Data curation, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  4. Yukiko Abe

    Center for Supercentenarian Medical Research, Keio University School of Medicine, Tokyo, Japan
    Contribution
    Data curation, Validation, Investigation
    Competing interests
    No competing interests declared

  5. Nobuyoshi Hirose

    Houtokukai Utsunomiya Hospital, Tochigi, Japan
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  6. Michiyo Takayama

    1. Center for Supercentenarian Medical Research, Keio University School of Medicine, Tokyo, Japan
    2. Center for Preventive Medicine, Keio University School of Medicine, Tokyo, Japan
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  7. Toru Takebayashi

    Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan
    Contribution
    Supervision, Funding acquisition, Project administration, Writing – review and editing
    Competing interests
    No competing interests declared

  8. Hideyuki Okano

    Department of Physiology, Keio University School of Medicine, Tokyo, Japan
    Contribution
    Supervision, Project administration, Writing – review and editing
    Competing interests
    received consulting fees from SanBio Co.Ltd and K Pharma Inc, and participates on the Advisory Board for both SanBio Co.Ltd and K Pharma Inc. The author is President of the Japanese Society for Regenerative Medicine and the Japanese Society for Neurochemistry. The author has no other competing interests to declare

  9. Yasumichi Arai

    Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan
    Contribution
    Conceptualization, Supervision, Investigation, Project administration, Writing – review and editing
    Competing interests
    has received a grant from the Cyclic Innovation for Clinical Empowerment (AMED EKID), and from DAIICHI SANKYO Co, Ltd. The author has no other competing interests to declare

Funding

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (21590775)

  • Nobuyoshi Hirose
  • Michiyo Takayama
  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (24590898)

  • Nobuyoshi Hirose
  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (15KT0009)

  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (18H03055)

  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (20K20409)

  • Takashi Sasaki
  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (20K07792)

  • Takashi Sasaki
  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (23H03337)

  • Takashi Sasaki
  • Yasumichi Arai

Japan Science and Technology Agency (JP15667051)

  • Toru Takebayashi
  • Yasumichi Arai

Japan Agency for Medical Research and Development (16kk0205009h001)

  • Yasumichi Arai

Japan Agency for Medical Research and Development (17jm0210051h0001)

  • Takashi Sasaki
  • Yasumichi Arai

Japan Agency for Medical Research and Development (19dk0207045h0001)

  • Takashi Sasaki
  • Yasumichi Arai

Keio University Global Research Institute

  • Hideyuki Okano
  • Yasumichi Arai

Kanagawa Institute of Industrial Science and Technology

  • Yasumichi Arai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Written informed consent was obtained either from the participant or from a proxy if the participant lacked the capacity to provide consent. The ethics committee approved all cohort studies of the Keio University School of Medicine (ID: 20021020, 20022020, 20070047, and 20160297). The TOOTH and KAWP studies are registered in the University Hospital Medical Information Network Clinical Trial Registry (ID: UMIN000001842 and UMIN000026053).

Senior Editor

  1. Carlos Isales, Augusta University, United States

Reviewing Editor

  1. Edward D Janus, University of Melbourne, Australia

Reviewer

  1. Sandra Aleksic, Albert Einstein College of Medicine, United States

Version history

  1. Preprint posted: June 30, 2022 (view preprint)
  2. Received: January 19, 2023
  3. Accepted: September 28, 2023
  4. Accepted Manuscript published: September 28, 2023 (version 1)
  5. Version of Record published: October 10, 2023 (version 2)

Copyright

© 2023, Sasaki et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 252
    Page views
  • 60
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Takashi Sasaki
  2. Yoshinori Nishimoto
  3. Takumi Hirata
  4. Yukiko Abe
  5. Nobuyoshi Hirose
  6. Michiyo Takayama
  7. Toru Takebayashi
  8. Hideyuki Okano
  9. Yasumichi Arai
(2023)
Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study
eLife 12:e86309.
https://doi.org/10.7554/eLife.86309

Categories and tags

Research organism

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology

    Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting

    Ian R Outhwaite, Sukrit Singh ... Markus A Seeliger
    Research Article

    Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicates the development of selective kinase inhibitors. Inhibition of off-target kinases makes it difficult to study the mechanism of inhibitors in biological systems. Current efforts focus on the development of inhibitors with improved selectivity. Here, we present an alternative solution to this problem by combining inhibitors with divergent off-target effects. We develop a multicompound-multitarget scoring (MMS) method that combines inhibitors to maximize target inhibition and to minimize off-target inhibition. Additionally, this framework enables optimization of inhibitor combinations for multiple on-targets. Using MMS with published kinase inhibitor datasets we determine potent inhibitor combinations for target kinases with better selectivity than the most selective single inhibitor and validate the predicted effect and selectivity of inhibitor combinations using in vitro and in cellulo techniques. MMS greatly enhances selectivity in rational multitargeting applications. The MMS framework is generalizable to other non-kinase biological targets where compound selectivity is a challenge and diverse compound libraries are available.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    Indole produced during dysbiosis mediates host–microorganism chemical communication

    Rui-Qiu Yang, Yong-Hong Chen ... Cheng-Gang Zou
    Research Article Updated

    An imbalance of the gut microbiota, termed dysbiosis, has a substantial impact on host physiology. However, the mechanism by which host deals with gut dysbiosis to maintain fitness remains largely unknown. In Caenorhabditis elegans, Escherichia coli, which is its bacterial diet, proliferates in its intestinal lumen during aging. Here, we demonstrate that progressive intestinal proliferation of E. coli activates the transcription factor DAF-16, which is required for maintenance of longevity and organismal fitness in worms with age. DAF-16 up-regulates two lysozymes lys-7 and lys-8, thus limiting the bacterial accumulation in the gut of worms during aging. During dysbiosis, the levels of indole produced by E. coli are increased in worms. Indole is involved in the activation of DAF-16 by TRPA-1 in neurons of worms. Our finding demonstrates that indole functions as a microbial signal of gut dysbiosis to promote fitness of the host.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics

    The neuronal calcium sensor NCS-1 regulates the phosphorylation state and activity of the Ga chaperone and GEF Ric-8A

    Daniel Muñoz-Reyes, Levi J McClelland ... Maria Jose Sanchez-Barrena
    Research Article

    The Neuronal Calcium Sensor 1, an EF-hand Ca2+ binding protein, and Ric-8A coregulate synapse number and probability of neurotransmitter release. Recently, the structures of Ric-8A bound to Ga have revealed how Ric-8A phosphorylation promotes Ga recognition and activity as a chaperone and guanine nucleotide exchange factor. However, the molecular mechanism by which NCS-1 regulates Ric-8A activity and its interaction with Ga subunits is not well understood. Given the interest in the NCS-1/Ric-8A complex as a therapeutic target in nervous system disorders, it is necessary to shed light on this molecular mechanism of action at atomic level. We have reconstituted NCS-1/Ric-8A complexes to conduct a multimodal approach and determine the sequence of Ca2+ signals and phosphorylation events that promote the interaction of Ric-8A with Ga. Our data show that the binding of NCS-1 and Ga to Ric-8A are mutually exclusive. Importantly, NCS-1 induces a structural rearrangement in Ric-8A that traps the protein in a conformational state that is inaccessible to Casein Kinase II-mediated phosphorylation, demonstrating one aspect of its negative regulation of Ric-8A-mediated G-protein signaling. Functional experiments indicate a loss of Ric-8A GEF activity towards Ga when complexed with NCS-1, and restoration of nucleotide exchange activity upon increasing Ca2+ concentration. Finally, the high-resolution crystallographic data reported here define the NCS-1/Ric-8A interface and will allow the development of therapeutic synapse function regulators with improved activity and selectivity.